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ABSTRACT
. A person is exposed to many pathogens throughout their lifetime, and with the
resolution of each infection, there remains a pool of pathogen-specific immune cells that
protect that person from re-infection with the same pathogen. However, there is a great
deal of evidence to suggest that the pool of pathogen-specific memory cells can also
participate in the immune response to future infections with unrelated pathogens. Many
believe T cells to be cross-reactive in nature because of their interaction with self
antigens during development in the thymus and their interaction with foreign antigens
once in the periphery. There are many features of the interaction between a T cell and its
ligand that facilitate this cross-reactive nature. Based on solved crystal structures
relatively few contacts are required for a stable interaction, and that interaction is often
mediated by the flexible CDR3 loops of the T cell receptor that accommodate ligands of
varous structure. There is also evidence in the murine and human systems that subsets of
virus-specific memory CD8 T cells take on an activated phenotype upon infection with
an unrelated virus. In murine models , these memory T cell subsets could kil target cells
secrete several cytokines, and proliferate in response to a cross-reactive stimulation
suggesting that a cross-reactive T cell response could impact the outcome of a viral
infection. In fact, upon heterologous infection, mice immune to a previous virus were
often protected, having lower titers of the second unrelated virus, their epitope-specific
and T cell receptor repertoires were often skewed, and they were more prone to immune-
mediated pathologies. All of these observations coincided with the presence of cross-
reactive T cell responses. Thus, we define heterologous immunity as changes in viral
V11
replication and the disease pathology associated with that viral infection as a result of the
host's history of infection , and this can be mediated, in part, by cross-reactive CD8 T cell
responses.
Since many human viral infections are associated with a wide range of disease
states , we questioned whether cross-reactive CD8 T cell responses occured as commonly
as they appeared to occur in the murine models and whether they influenced the outcome
of such infections. Epstein-Bar virus (EBV) infects over 90% of the U. S. population
and has a large genome with the capacity to encode a multitude of T cell epitopes. The
first part of this thesis research focuses on the identification of cross-reactive CD8 T cell
responses with specificity for known epitopes derived from EBV, a common human
virus. We directed our study to HLA-A2-restricted responses because of the common
expression of this MHC Class I allele in the U. S. population. This study resulted in the
detection of cross-reactive responses with five different specificities that involved either
the immunodominant lytic EBV -BMLF1 28o epitope or the latent EBNA 3As96 epitope.
Three of the cross-reactive responses had specificity for epitopes derived from another
unrelated, but common, human virus, influenza A virus (IV). Each of these cross-
reactive responses had the potential to participate in the collective immune response to
acute EBV infection.
EBV is also well-suited as a model system to study heterologous immunity in
humans , as infection at an early age is frequently asymptomatic , while the same infection
during adolescence often results in an immune-mediated syndrome infectious
mononucleosis (1M). Since older individuals have presumably been exposed to more
Vll
pathogens in their lifetime and, therefore, would have memory CD8 T cell pools with
more extensive specificities , we hypothesized that acute EBV infection activated cross-
reactive memory CD8 T cell responses that promoted the development of 1M. In order to
determine if the cross-reactive responses we identified above contributed to the immune
response to acute EBV infection, we first screened the blood of 1M patients for cross-
reactive T cells with specificity for EBV-BMLF1 28o and IV-MIs8. The total number of
MI-specific T cells of 5 of 8 patients was increased at presentation with 1M, which was
suggestive of their specific activation during the EBV infection since a bystander
mechanism would have resulted in 8 out of 8 patients having increased numbers of M 
specific T cells. Our hypothesis was further supported by the fact that we clearly
detected cross-reactive T cells capable of recognizing both BMLF1 and M1 epitopes in
the blood of 2 of the 5 1M patients with an augmented M1-specific T cell frequency.
Furthermore, the M1-specific TCR repertoires of those two patients were dramatically
skewed, which was an indication of cross-reactive M1-specific T cell expansions and
therefore, participation in the lymphoproliferation characteristic of 1M. In addition, T
cell lines derived from 3 out of 8 healthy donors with previous exposure to both viruses
contained a subset ofT cells that responded to both BMLF1 and M1 epitopes , suggesting
that these cross-reactive cells are often maintained in memory. These cross-reactive T
cells were cytotoxic and produced MIP- 1 p, IFNy, and TNFa , functions which could
potentially promote the symptoms of 1M and, indeed, may have been contributed to the
severe case of 1M noted in one patient.
The final part of this thesis research focused on defining the structure of the cross-
reactive TCR that recognized both BMLF1 and M1 epitopes, which have only 33%
sequence similarity. In addition, we examined the cross-reactive TCR repertoire
organization of multiple individuals to determine the breath and, therefore, the likelihood
that this cross-reactive T cell response wil occur. These studies revealed that a wide
range of Va and Vp families can mediate interaction with both epitopes and that the
cross-reactive TCR repertoire was unique to each individual, relying heavily on the T cell
clones present in that individual' s private BMLF1- and MI-specific repertoires. We also
observed an increased frequency of TCRs with longer CDR3 regions within the cross-
reactive repertoire, which were often extended by non-bulky amino acid residues that
could provide these TCRs with more flexibility in order to accommodate the two
different epitope structures.
Given that we detected a cross-reactive T cell response with specificity for two
immunodominant epitopes derived from two of the most common human viruses among
people that share one of the most common MHC Class I alleles in the U. S. population
we predict that cross-reactive T cells are common components of human immune
responses. The variability in the magnitude and specificity of each cross-reactive T cell
response is dependent on each individual's unique history of infection and th eir unique
TCR repertoire, and such responses likely represent one of many factors that could
explain the individual varability in disease severity associated with EBV and many other
human viral infections.
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CHAPTER I:
INTRODUCTION
Memory CD8 T cells represent a vital component of the immune system that
provide protection against re-infection with previously encountered pathogens, such as
vIruses. Memory T cells have been primed and are able to interact with peptide-MHC
(PMHC) complexes on non-professional antigen-presenting cells (APC) in peripheral
tissues. These memory cells are present at higher precursor frequencies than naIve T
cells and have fewer requirements for activation, as they are able to respond to lower
concentrations of antigen and are less dependent on co-stimulatory signals (reviewed in
(Dutton et al. , 1998; Sprent and Surh, 2002; Welsh et al. , 2004)). Thus , antigen-specific
memory CD8 T cells are at the site of infection earlier, are initially present at higher
numbers, and are more easily activated than antigen-specific naIve CD8 T cells. These
characteristics put memory cells at an advantage when fighting re-infection with an
invading virus.
There are currently many examples, in both murne and human systems, which
suggest a CD8 T cell can recognize and respond to more than one viral antigen
(Anderson et al. , 1992; Brehm et al. , 2002; Kuwano et al. , 1991; Mathew et al., 1998;
Mongkolsapaya et al. , 2003; Nilges et al. , 2003; Wedemeyer et al. , 2001). 1fT cell cross-
reactivity occurs frequently, then memory CD8 T cells are not only at an advantage when
fighting re-infection with a previously encountered virus but, for the same reasons, a
subset of cross-reactive memory cells are also at an advantage when confronted with a
new, unrelated, virus. Evidence generated in controlled experiments using a murine
model system of heterologous virus infection suggests that cross-reactive CD8 T cell
responses commonly occur and can influence the outcome of infection. Our lab has
identified several cross-reactive CD8 T cell responses and has demonstrated that
immunity to a previous viral infection can 1) provide at least some protection against
challenge with an unrelated virus, as evidenced by lower virus titers and 2) result in
immune-mediated pathology following challenge with an umelated virus, which is
distinct from the disease pathology typically observed in naIve mice challenged with the
same virus (reviewed in (Welsh and Selin, 2002)). We have termed this phenomenon
heterologous immunity.
The goal of this thesis research was to determine if cross-reactive CD8 T cell
responses were common during human viral infections and if they influenced the
outcome of an infection. To determine whether cross-reactive CD8 T cell responses were
a common component of the human immune response to viral infection, we focused our
research on one of the most commonly expressed MHC Class I alleles in the U. S. , HLA-
A*0201 , and concentrated our efforts on the immune response to two of the most
common human viruses , Epstein-Barr virus (EBV) and influenza A virus (IV). Using
these guidelines , we screened the blood of several individuals for the presence of cross-
reactive CD8 T cells. T cell receptor (TCR) repertoire analyses were also employed to
reveal any structural requirements a TCR must meet to engage more than one ligand
which may help determine how often such cross-reactive TCRs appear within a given
memory T cell pool and among different individuals. EBV infection was also a good
model system for determining whether heterologous immunity influenced the outcome of
human viral infections. . Primary EBV infection later in life frequently results in a CD8 T
cell-mediated pathology known as infectious mononucleosis (1M), so we aimed to collect
blood samples from 1M patients throughout the acute phase of their infection to monitor
the presence of cross-reactive CD8 T cell responses and disease severity.
This introduction is separated into more detailed discussions on individual topics
as they pertain to this thesis research.
A. Definition of T cell cross-reactivity
T cell cross-reactivity is defined here as the basic biological observation that a
given T cell can interact with multiple ligands presented by the same self-MHC molecule.
However, it is noted that T cell cross-reactivity also includes T cells that recognize
allogeneic MHC molecules (ie. allo-reactivity) as well as T cells that recognize cross-
species MHC molecules (ie. xeno-reactivity). This thesis is focused on defining virus-
specific cross-reactive CD8 T cell responses and demonstrating the biological
consequences of these responses on human disease. In keeping with this focus, virus-
specific cross-reactive CD8 T cell lines and clones have already been identified. Viral
cross-reactivity can involve the recognition of different proteins expressed by the same
virus (Anderson et al. , 1992; Kuwano et al. , 1991), different viral serotypes (Mathew et
al., 1998; Mongkolsapaya et al. , 2003), and unrelated viruses (Acierno et aI., 2003;
Nilges et al. , 2003; Wedemeyer et al. , 2001). However, it is stil unclear how prevalent
cross-reactive T cells are among the human population and what role they play in the
immune response to viral infection.
During their development in the thymus, CD4 and CD8 single-positive T cells
undergo positive and negative selection processes (reviewed in (Starr et al. , 2003)).
Positive selection requires a productive, but low avidity, interaction with a self-peptide in
the context of a self-MHC molecule which elicits survival and maturation signals. In
contrast, a high avidity interaction would reveal a T cell' s autoimmune tendency and
would signal the negative selection or deletion of that T cell from the naIve repertoire.
Thus upon entering the periphery, a naIve T cell already has a low level of specificity for
a self-peptide. In order to fully mature into an effector or memory T cell, this naiVe T
cell must also interact with a foreign peptide. Experiments that demonstrated a naturally
processed self-peptide was recognized by a defined antigen-specific T cell clone during
its development in the thymus help support the claim that each effector and memory T
cell in the periphery is cross-reactive in nature (Hogquist et al. , 1997; Hu et al., 1997;
Sasada et al. , 2001; Tallquist et al. , 1996).
The most comprehensible .mechanism of cross-reactivity involves molecular
mimicry, where a T cell can use the same receptor elements to interact with multiple
different ligands that are largely similar in sequence and structure (Figure 1) (Anderson et
al. , 1988; Fujinami and Oldstone, 1985; Guillet et al., 1987; Welsh and Selin, 2002).
However, it is now clear that cross-reactive mechanisms can be more complex, as a T cell
can also interact with peptide ligands having little to no sequence or structural similarity
(Bhardwaj et al. , 1993; Boen et al. , 2000; Evavold et al. , 1995; Reiser et aI. , 2003; Zhao
et al. , 1999). Under such circumstances, the T cell receptor (TCR) may use different
receptor elements to interact with each ligand, referred to as an alternative recognition
mechanism (Figure 1). The lack of conserved structural requirements for interaction
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between a gIVen TCR and its ligand makes predicting cross-reactivity diffcult.
Nevertheless, cross-reactive T cell interactions are known to occur in nature and can be
an active component of the host immune response (Brehm et al. , 2002; Cornberg et al.
2005a; Selin et al. , 1994; Urbani et al. , 2005; Wedemeyer et al. , 2001). This thesis will
address how often such dross-reactive T cell responses occur and if they influence the
outcome of a human viral infection.
B. Cross-reactive CDS T cells and heterologous immunity
Heterologous immunity has been described in murine models of viral infection
whereby memory CD4 and CD8 T cells specific to a previous infection protect the host
at least partially, from a subsequent unrelated infection and can also change the disease
pathology associated with that infection (Selin et al. , 1998; Welsh and Selin, 2002). For
example, a memory T cell response to lymphocytic choriomeningitis virus (LCMV)
protected mice against infections with either Pichinde virus (PV) or vaccinia virus (VV)
based on reduced viral titers and survival to an otherwise lethal dose of VV. The
mechanism behind this protection is stil under investigation and is likely to depend on
the virus involved. While cytotoxicity may playa prominent role in the context of one
infection, cytokine production may be more important in the context of another. In the
case of a VV challenge, it was determined that IFNy played a role in the reduction 
virus titer (Chen et al. , 2001; Selin et al. , 1998). LCMV-specific memory CD8 T cells
detected at the site of infection correlated with this protection and were shown to produce
IFNy following this cross-reactive VV stimulation (Chen et al. , 2001). Furthermore, our
lab has more recent evidence that the transfer of cross-reactive LCMV -specific T cell
lines alone could mediate a reduction in VV titer, the extent of which appeared to be
influenced by the cross-reactive specificity and TCR repertoire of those T cell lines
(Comb erg et al. , 2005a). Individual variations in cross-reactive specificity patterns and
the cross-reactive TCR repertoire can influence heterologous immunity and are discussed
later under the topic of prIvate specificity.
Cytotoxicity and cytokine secretion by cross-reactive memory CD8 cell
populations can also promote or alter the disease pathogenesis associated with a viral
infection. While surviving an otherwise lethal dose, LCMV-immune mice often
presented profound immunopathology as a result of acute VV infection that differed with
the site of infection. An intraperitoneal infection resulted in T cell infitration of the fat
and a condition known as acute fatty necrosis (Selin et al. , 1998; Yang et al., 1985).
Intranasal infection resulted in the infitration of LCMV -immune T cells into the
bronchus-associated lymphoid tissue and, in some cases, a condition known as
bronchiolitis obliterans, where the bronchioles are obstructed with fibrin and
inflammatory cells (Chen et al. , 2001). This is opposed to pulmonary edema more
typical of acute VV infection, where the airways in the lung are fluid-filled. The
presence of IFNy appeared to playa role in both acute fatty necrosis and the regional
expansion of bronchus-associated lymphoid tissue and, as stated above, we demonstrated
that cross-reactive LCMV-specific memory cells can contribute to the total level of
IFNy production. Activated CD8 T cells can also produce significant levels of TNFa
which has been shown to initiate pulmonar tissue damage during an influenza virus
infection (Xu et al. , 2004). We are currently investigating the role ofTNFa in these VV-
associated pathologies and any contribution made by these activated cross-reactive T
cells.
The potential role of cross-reactive T cells in the disease pathogenesis associated
with human viral infections is now being appreciated. For example, it is known that
cross-reactive CD8 T cells exist that recognize highly similar epitopes derived from
different serotypes of Dengue virus and that the activation and proliferation of T cells
correlated with heightened disease severity, or the development of Dengue hemorrhagic
fever (Mathew et al., 1998; Mongkolsapaya et aI. , 2003; Zivna et al., 2002). One
speculated mechanism for this disease pathology involves TNFa , which has been shown
to cause capilary plasma leakage and can lead to shock (Rothman and Ennis, 1999;
Vassall, 1992). Cross-reactive T cell responses may also influence the immune response
to hepatitis C virus (HCV) infection, as a subset of IV -specific memory cells have been
shown to co-recognize a highly similar epitope derived from HCV, and the proliferation
of these cells correlated with severe acute liver pathology and resulted in a chronic HCV
infection (Urbani et al. , 2005). Thus, an increasing amount of evidence is suggestive that
an individual's history of infection largely impacts future immune responses , and this
may be one of the many factors that explain the individual variation in the disease state
associated with a given viral infection.
c. T cell activation by altered peptide ligands
Given their potential role in virus protection and associated disease pathologies
investigations into the extent of activation and the resulting effector functions of cross-
reactive T cells are paramount. Synthetic variants of a native peptide, termed altered
peptide ligands (APL),. have been shown to stimulate a given TCR to its fullest extent
(agonist), to a lesser extent (partial or weak agonist), or not at all (antagonist) due to their
inability to induce a signal and their ability to block interaction with nearby agonists
(Sloan-Lancaster and Allen, 1996). While a low avidity interaction with an APL is
frequently insuffcient to elicit full effector function, an increase in the concentration of
that APL, combined with the signal generated from the CD8 co-receptor, has been
reported to compensate for such a weak or transient TCR engagement (Couedel et al.
1999; Holler and Kranz, 2003; Reichstetter et al., 1999). These data suggested that a
threshold of T cell activation existed, perhaps for each individual function, and that in
order for a T cell to reach its functional potential, this threshold(s) must be met.
Alternatively, there is evidence to suggest that the TCR signal generated following
ligation with an APL is qualitatively different from that following ligation with the native
peptide (Madrenas and Germain, 1996; Sloan-Lancaster and Allen, 1996). These data
suggested that the functional response of a T cell may be dependent on the structure of
the ligand and that there are no compensatory mechanisms with which to gain full
effector function upon interaction with a variant ligand. Based on this theory, each
peptide ligand may be responsible for inducing an allosteric change that accommodates
binding between the antigen presenting cell (APC) and T cell co-receptors and initiates a
unique signal transduction cascade (Madrenas and Germain, 1996).
There are still other models that have been proposed to explain the mechanism
behind the differential T cell functions elicited by an APL, thus , the true mechanism is
still unkown and may involve aspects of several current models (Madrenas and
Germain, 1996). What is clear is that the functions resulting from TCR engagement with
an APL can have profound biological effects. In the periphery, mature T cells that
engage APLs can become anergic or secrete an altered pattern of cytokines that not only
influences its own function but influences the differentiation and function of neighboring
immune cells (Windhageh et al. , 1995). We predict that cross-reactive interaction with
natural APLs will have a similar effect and that this may impact the development of an
efficient immune response and promote T cell-mediated pathogenesis.
D. Concept of private specifcity
As alluded to earlier, during the discussion of heterologous immunity, individual
variability in the cross-reactive specificity patterns and in the cross-reactive TCR
repertoire have the potential to influence the outcome of a viral infection. For instance
while LCMV-immune mice are generally protected from a lethal VV challenge, the
extent of the reduction in VV titer and the degree of associated immunopathology varied
between individual mice, results which were suspected to be an effect of the different
cross-reactive specificity patterns that occurred (Kim et al. , 2005). In addition to the
observed differences in the specificity of the cross-reactive T cell responses of each
mouse, cross-reactive T cell lines having similar specificity were derived from some of
these mice but were comprised of different cross-reactive T cell clones with varable
avidity for their VV-encoded ligand (Comb erg et al. , 2005a). Thus, clonal differences
may have influenced the level of protection these cross-reactive T cell lines conferred
when transferred to VV -challenged hosts.
Individual variations of the cross-reactive specificity pattern and ofthe cross-
reactive TCR repertoir likely reflect the unique clonotypic composition of each host's T
cell repertoire prior to VV challenge. An investigation of naIve T cell repertoires
revealed clonal variations between genetically identical mice, presumably a result of the
random TCR gene rearrangements and the stochastic selection pressures endured during
T cell development (Bousso et al. , 1998). These clonal variations can cause variations in
the antigen-specific T cell repertoires of individual mice following the same
immunization or infection, which may be even more apparent due to the added stochastic
process of encountering their specific antigen presented on the appropriate APC (Bousso
etal. , 1998; Cibotti et al. , 1994; Cornberg et al. , 2005b; Kim et al. , 2005; Lin and Welsh
1998). Therefore, despite the possibility of having comparable epitope-specific
hierarchies , the clonal composition of each of those epitope-specific responses will differ
between individuals , and this phenomenon has been referred to as the private specificity
of each individual' s T cell repertoire.
While the private specificity of each antigen-specific T cell repertoire ensures that
each immune response is unique, often there are also public features of each repertoire
that are shared between unrelated individuals. T cells activated by a given peptide-MHC
complex generally share conserved TCR features that are necessary for a stable
interaction, such as conserVed Va or Vp family usage or the expression of C:QR3 amino
acid motifs. It has been postulated that the public specificity of a T cell repertoire is
influenced by the structure of the peptide ligand; for instance, a peptide lacking
prominent side chains may require contact with a strict, and therefore public, TCR
structure having the features necessary for contact (Stewart-Jones et al. , 2003; Turner et
al. , 2005). According to this theory, a peptide with upfacing side chains of its own may
be able to mediate contact with a wider variety of less conserved TCR structures (Turner
et al. , 2003; Turner et al. , 2004). While peptide structure may indeed playa role in the
formation of an antigen-specific T cell repertoire, it is unlikely to be the only factor
involved.
Unlike public features of a repertoire which may be easier to predict, the private
specificity of each repertoire adds another layer of complexity to the study of T cell
cross-reactivity. The individuality of each T cell response makes comparing patients
diffcult and may prevent any generalizations from being made regarding the presence
and influence of a given cross-reactive CD8 T cell response on an acute viral infection.
However, the private specificity of each individual's T cell repertoire is likely to be
another factor contributing to the variability in disease severity associated with many
human viral infections.
E. T cell receptor structure and recognition of the peptide-MHC complex
Given the potential influence of the T cell repertoire on human disease and the
need to determine how frequently a cross-reactive T cell interaction occurs, it is
important to understand the basic principles of TCR structure and the interaction between
a TCR and its peptide-MHC complex (pMHC). Such knowledge may reveal how easy 
difficult it is for a given TCR to engage a variant ligand, particularly in a case where the
putative variant ligand has little structural similarity to the native ligand.
We chose to focus our initial research on CD8 T cell responses restricted by
HLA-A*0201 , one of the most common MHC Class I alleles in the U. S. population and
representing 55% of our study cohort. HLA-A2*0201 preferentially binds peptides 9
amino acids (aa) in length that have a specific binding motif. Positions 2 and 9 of the
peptide sequences commonly contain IlL or LIV residues, respectively, and the side
chains of these anchor residues generally insert into two pockets at the opposite ends of
the peptide-binding groove (Engelhard, 1994).
The TCR that recognizes these pMHC complexes exists as a heterodimer of one
alpha (a) and one beta (P) chain in association with a membrane-bound complex of CD3
proteins (Janeway et al. , 1999). The a-chain of the heterodimer is comprised of one
variable (V), one junctional (J), and one constant (C) gene, while the p-chain 
comprised of one V , one diversity (D), one J, and one C gene. The presence of multiple
, D , and J genes enhances the variability of the developing TCR repertoire, and the
various combinations of these genes , through the process ofV(D)J recombination, further
enhance this variability. Upon joining two of these genes , some of the germline encoded
nucleotides may be lost and some non-germline encoded nucleotides may be added to the
junction region (N-additions). All of these factors contribute to the diversity of the TCR
repertoire so that it may recognize a wide range of foreign antigens.
To fully understand the strcture and function of cross-reactive T cells as they
pertain to human disease, it is important to review the current theories surrounding the
interaction between a TCR and the pMHC. Contact with the pMHC is generally
mediated by 6 loops that protrude from the TCR heterodimer, 3 from each chain (Figure
2). Therefore, these loops have been termed the complementarity-determining regions
(CDR) because they form a surface complementary to the antigen. CDR1 and CDR2 of
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each chain are germlin encoded by the V gene, therefore, T cell clones expressing the
same V gene have little diversity between them in these regions. However, CDR3
represents the junction region where the V , D , and J genes combine , making this the most
variable sequence of the TCR. The sequence of the CDR3 loop defines each unique T
cell clone and, therefore, is commonly used for TCR repertoire analyses.
Based on at least 20 solved crystal structures , 8 of which involve a human TCR
bound to peptide presented by HLA- , it is thought that the TCR orients itself
diagonally over the peptide-MHC complex (Buslepp et aI. , 2003; Chen et al., 2005;
Garcia et al., 1999; Housset and Malissen, 2003; Maynard et al. , 2005; Rudolph and
Wilson, 2002; Stewart-Jones et al. , 2003). Although, there are exceptions to this rule
such as the orthogonal orientation of the JM22 TCR over influenza Ml /HLA-A *0201
(Buslepp et al. , 2003; Stewart-Jones et al. , 2003). Due to this semi-conserved orientation
the TCR a-chain is generally positioned over the amino-terminus of the peptide and the
TCR p-chain is generally positioned over the carboxy-terminus of the peptide. Although
both chains are involved in the interaction with the pMHC , the solved crystal structures
would suggest that slightly more of the interaction is mediated by the a-chain, which can
make significant contributions to the stability of the complex .(Rudolph .and Wilson
2002). The kinetics of the interaction have been described in a 2-step model whereby the
TCR first makes contact with the MHC molecule, which facilitates peptide scanning,
followed by a stable interaction between the TCR and its native peptide ligand (Wu et al.
2002). In this model, TCR docking to the MHC, or step 1 , is likely mediated through the
CDR1 and CDR2 .loops of the TCR, which have a more rigid structure and less variable
sequence than the CDR3 loops (Chothia et al. , 1988; Davis and Bjorkman, 1988; Garcia
et al. , 1999; Wu et al. , 2002). Contact with the peptide, or step 2, is likely mediated
through the CDR3 loops that are better positioned over the central area of the peptide so
to contact any side chains that are up facing (Figure 2). Furthermore, the more flexible
nature of the CDR3 loops allows them to fold over the peptide and make more stable
contacts (Wu et al. , 2002). However, there has been some controversy over the validity
of this model as examples arise that do not appear to fit the rule. A revision of the model
has since been suggested whereby the peptide ligand involved dictates which CDR loops
carry the largest energetic burden of the interaction (Borg et al. , 2005). Peptide ligands
can vary significantly in their structure, which may bulge out towards the TCR presenting
prominent side chains or may lay rather featureless buried within the MHC binding
groove. One theory that has been put forth in the field is that peptides with fewer
prominent features may require a strict TCR structure with prominent features of its own
to initiate contact with the pMHC (Stewart-Jones et al. , 2003; Turner et al. , 2005). This
theory appears to apply to at least one of the peptides used in our research, IV- , and it
will be interesting to test it in the context of CD8 T cell cross-reactivity (Stewart-Jones et
al. , 2003).
F. Cross-reactive T cell receptor structure
The knowledge and concepts that have evolved from previous studies of the TCR-
pMHC interaction, as briefly reviewed above, have led to several potential mechanisms
behind the interaction between a cross-reactive TCR and its alternative ligand (Figure 1).
Although it may be an exception to the rule, up to 30% of T cells in the periphery are
thought to express two different TCRs on their surface. Dual TCR expression can result
from the expression of two different p-chains or, more commonly, from the expression of
two different a-chains due to inefficient allelic exclusion during development
(Balomenos et al. , 1995; Casanova et al. , 1991; Davodeau et aI. , 1995; Padovan et al.
1993; Padovan et al., 1995). Using a murine system, both TCRs were shown to be
functional and,. thus , it has been speculated that dual TCR expression is one mechanism
by which a T cell can broaden its specificity (Figure 1) (He et al. , 2002; Welsh and Selin
2002). However, this is only one potential mechanism ofT cell cross-reactivity.
Through comparison of the unliganded and liganded crystal structures of a TCR
we can infer that conformational changes, small or large, allow the TCR to form a
successful interaction with a pMHC (Garcia et al. , 1998). Such conformational changes
are often mediated by the TCR CDR3 loops. Their characteristic flexibility likely stems
from their variable length and sequence, where longer loops containing multiple non-
bulky aa residues , such as glycine, have fewer constraints to alleviate upon engaging the
pMHC (Abergel and Claverie, 1991; Bentley and Mariuzza, 1996; Garcia et al., 1999;
Hare et al., 1999; Reiser et al., 2002). Although the TCR makes this effort to
accommodate the structure of its ligand, relatively few contacts between a TCR and its
peptide appear necessary for a stable interaction; based on the solved crystal structures, a
CD8 TCR generally only makes direct contact with positions 5, 7 and 8 of a 9-mer
peptide sequence (Bjorkman; 1997; Rudolph and Wilson, 2002). In fact, a single aa
residue, representing the primary TCR contact site, may be the only essential component
shared among peptide ligands recognized by a given TCR (Evavold et al. , 1995). The
large amount of space left between a TCR and its peptide-MHC is filled with water
molecules that become equally important to the specificity of the interaction (Rudolph
and Wilson, 2002).
The ability to accommodate various ligand structures through conformational
change, the relatively 'few contacts with peptide , and the overall poor shape
complementarity between a TCR and the peptide-MHC complex are all qualities of the
interaction that facilitate T cell cross-reactivity (Garcia et al. , 1998; Willcox et al. , 1999).
Crystal structures of the same human TCR bound to multiple different peptide ligands in
the context of HLA-A2 provided the first clues as to mechanism behind a cross-reactive
interaction, where most of the structural adjustments were mediated by the CDR3p loop,
which contained three . glycine residues (Ding et al., 1999). However, there were
surprisingly few differences in the overall conformation of these crystal structures, which
may be explained by the fact that each of the ligands differed by only 1 aa residue. The
first crystal structures comparing a TCR engaged to two different ligands having no
sequence similarity revealed a much larger structural adjustment, which was again
mediated by a CDR3 loop, specifically CDR3a (Reiser et al., 2003). The authors
suggested that these two peptide ligands had completely different structures, and their
data supported a conformer hypothesis whereby an unliganded TCR is at equilibrium as a
dynamic population of conformations until engaging a peptide ligand that will shift the
equilibrium in favor of only one of those TCR confonnations (Gagnon et al. , 2005).
Others have suggested that any initial structural dissimilarity between ligands is
irrelevant because, upon interaction all ligands are molded to fit a conserved
conformation necessary' for specific TCR recognition (Lee et al. , 2004).
Although the exact mechanism(s) behind a cross-reactive TCR interaction is
largely unresolved, it is now accepted that a given T cell can interact with multiple
different peptide ligands, with or without a high degree of sequence or structural
similarity between them. ' One of the aims of this thesis research is to determine how
frequently cross-reactive TCR interactions occur, and it will be interesting to see how
many, if any, of these potential mechanisms of T cell cross-reactivity apply in our model
system.
G. Epstein-Barr virus
To study CD8 T cell cross-reactivity and heterologous immunity, we chose EBV
as our model system because of its high infection rate, its ability to induce an immune-
mediated disease, and its large genome size, which increases its potential to encode
multiple T cell epitopes that may elicit cross-reactive CD8 T cell responses. Thus, it is
important to understand the biology of this virus and how it might activate a CD8 T cell
response. EBV, also known as human herpesvirus 4 (HHV4), is a viral species of the
Lymphocryptovirus genus and of the Gammaherpesvirinae subfamily that infects over
90% of the U. S. population. It has a large double-stranded DNA genome of 184kbp.
EBV is released into and spread through saliva. Although epithelial cells, and possibly T
cells and NK cells , can become infected in vivo and support viral replication during the
lytic stage of the viral life cycle, EBV primarily infects resting naive B cells found in the
secondary lymphoid tissue ofWaldeyer s tonsilar ring and uses CD21 and MHC Class II
molecules as its receptor and co-receptor respectively (Thorley-Lawson and Gross , 2004;
Young and Rickinson, 2004). EBV likely exploits B cell biology to establish a life-long
persistent infection within its host, transitioning through different transcriptional
programs that appear to drve the B cell through its normal stages of differentiation
(Figure 3) (Thorley-Lawson and Gross, 2004; Young and Rickinson, 2004). Upon
infection of a naIve B cell, EBV enters its growth program, or type III latency stage
which appears to activate the cell to become a proliferating lymphoblast. At this time
the infected B cell does not encode any lytic viral proteins but can express epitopes
derived from all 9 latent viral proteins on its surface and has the potential to activate both
CD4 and CD8 T cells. Transition to the default program, or type II latency stage, appears
to promote the survival of the lymphoblast and to support its differentiation into a
memory B cell, in a process that resembles a germinal center reaction. This process
involves the expression of only 3 of the latent viral proteins and, therefore, the number of
T cell epitopes is reduced at this stage of the viral life cycle. Upon B cell differentiation
the virus transitions to its latency program, or type I latency stage, and remains at this
stage for the lifetime of the memory B cell. Except for occasional EBNA- 1 expression
the virus ceases all gene expression during this time and virtually escapes T cell
recognition as the memory B cell circulates through the peripheral blood, however T cell
responses directed at EBNA- 1 have been identified (reviewed in (Munz, 2004)). It is not
until the B cell is further activated by a non-EBV driven mechanism that it completes
differentiation into an antibody-secreting plasma cell , and EBV once again initiates its
replication cycle, or lytic phase. A memory B cell undergoing this final stage of
differentiation has initiated viral replication, is located in the lymphoid tissue, and is
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likely to be the maj or target of the EBV -specific CD8 T cell response.
H. CDS T cell response to acute EBV infection
Although EBV is never completely eliminated from its host, there are several
reasons to believe that CD8 T cells are largely responsible for controllng viral replication
through the detection and destruction of infected host cells that express EBV -derived
epitopes. The rapid reduction in virus shedding and in the proportion of latently infected
B cells in the blood observed at convalescence implies effective T cell-mediated lysis of
infected target cells (Rickinson and Kieff 2001). Furthermore cell
immunocompromised individuals often cannot effectively control a primary infection
with EBV or lose their ability to control a pre-exisiting latent EBV infection, resulting in
increased levels of virus shedding and increased numbers of infected B cells in the blood
(Rickinson and Kieff, 2001). As a result, immunocompromised individuals can develop
EBV -induced B cell lymphomas and, it is interesting to note, that immunotherapeutic
attempts involving the transfer of polyclonal preparations of activated EBV -specific
donor Tcells frequently reversed tumor growth in the recipient and restored immune
control over viral replication (Rickinson and Kieff, 2001).
The CD8 T cell response to acute EBV infection is detectable following a 2-
week virus incubation period, coincident with a noticeable increase in the number of
infected B cells (Iwatsuki etal. , 2004). Most of what is known regarding the primary T
cell response to EBV is based on studies of adolescents because they acquire primary
EBV infections more frequently than adults and their immune response is greater in
magnitude than that of children with primary EBV infection. These studies revealed that
the CD8 T cell respons was directed against both latent and lytic EBV proteins and
could comprise up to 47% of all CD8 T cells in the peripheral blood, as reported in some
adolescents with infectious mononucleosis, an EBV -associated pathology that will be
discussed separately (Callan et al. , 1998; Catalina et al. , 2001). While the primary
response to latent proteins is delayed and of lower frequency than the primary response to
lytic proteins, CD8 T cell reactivity has been detected against several latent proteins
most frequently the EBNA- proteins (Callan et al., 1998; Catalina et al., 2001;
Rickinson and Moss , 1997; Steven et al. , 1997; Tan et al. , 1999). Those known to be
restricted by HLA-A2 and the frequency range of primary T cells specific for them are
noted in Table 1.
In addition to the viral proteins expressed at various points during the latent stages
of the viral lifecycle, the lytic stage includes the expression of at least 60 viral proteins
(Tierney et al. , 1994). The CD8 T cell response to lytic viral proteins occurs earlier and
is of a greater magnitude than the CD8 T cell response to latent viral proteins (Callan
2003; Catalina et al., 2001). Imediate-early lytic proteins are transactivators
responsible for initiating the transcription of many cellular and viral genes, and derive
many immunodominant CD8 T cell epitopes (Pudney et aI. , 2005). Early lytic proteins
are largely involved in viral DNA synthesis and are also the source of several
immunodominant epitopes. The late lytic proteins include the envelope glycoproteins
and are less frequently the source of immunodominant epitopes. Primary CD8 T cell
responses specific for lytic viral proteins, and which are restricted by HLA- , can be
found in Table 1. During the primary response, EBV -specific T cells typically express
Table 1. HLA-A2-presented, EBV-derived, latent and lytic cycle epitopes
and the frequency range of CD8 T cells specific for them.
A L t a en cyc e 0 a nmary emory
ito aa se uence Reference res onders T cell fre T cell fre
BARFO LLWAARPRL (Kienzle et aI. , 1998) 0% (O%f
EBNA-2As4-
***
(Schmidtetal., 1991)
EBNA- 596-604 SVRORLARL (Burrows et aI. , 1994) 10% (70%f 05- 06% 05-0.4%
EBNA- 284 293 LLOFVRFMGV (Kerr et aI., 1996) NO (60%f 270 pCTU1 D. PBMC'
LMP- 125 133 YLLEMLWRL (Khanna et aI. , 1998) 0% (0-70%f 102 pCTU10. PBMC'
LMP- 159 167 YLQQNWWTL (Khanna et aI. , 1998) 0% (14-55%f 09- 5% +
LMP- 329 337 LLWTLWLL (Lee et aI. , 1996) 0% (O%f
LMP- 356 364 FL Y ALALLL (Lautscham at aI. , 2003)
LMP- 426-434 CLGGLL TMV (Lee et aI. , 1993) 11% (63-75%) 1%0 05-0.4% 0
B. Lytic cycle % of A2+ primary Memory
ito aa se uence Reference res onders T cell fre T cell fre
BALF- 276 284 FLOKGTYTL (Pudney et aI. , 2005) 22% (ND)9
BALF- (Pudney et aI. , 2005) 33% (NO)9
BBRF- (Pudney et aI., 2005) 11% (NO)9
BHLF- (Pudney et aI. , 2005) 11% (NO)9 
BMLF- 280 288 GLCTLVAML (Scotet et aI. , 1996) 100% (91-100%) 08-47% 0 0.05-
(Steven et aI. , 1996)
BMRF- 208 216 TLOYKPLSV (Hislop et aI. , 2002) 100%( 17 -44 0;( )0 0. 05-1%0
BRLF- 109 YVLOHLlVV (Saulquin et aI. , 2000) 100% (75-100%) 34%0 05-2.4%0
BZLF- FMVFLQTHI (Stuber et aI. , 1995) 63% (12%f 01- 01- 15%
GP350863 871 VLQWASLAV (Khanna et aI. , 1999) 25% (O%f
GP85225 233 SL VIVTTFV (Khanna et aI. , 1999) 50% (25%f
GP85420-428 TLFIGSHW (Khanna et aI. , 1999) 50% (15%f
GP85542 550 LMIIPLINV (Khanna at aI., 1999) 50% (33-50% + 20-22 pCTU10. PBMC'
0;( f A2 P .
* Percent of HLA-A2+ people with T cells of this specificity during the acute
phase of EBV infection or, as shown in parenthesis , during the persistent phase
of EBV infection, ** frequency is of total COB T cells unless otherwise stated
***
QLSOTPLlPL TIFVGENTGV, + based on IFNy production as reported by
(Bharadwaj et aI. , 2001; Catalina et aI. , 2001), 0 based on tetra mer staining
reported by (Hislop et aI. , 2002), based on specific lysis of target cells by T cell
clones reported by (Pudney et aI. , 2005), NO: not sufficiently determined or notreported 
activation markers sue!) as CD45RO, CD38 , HLA- , CD69 , CD244 (or 2B4), and
downregulate the expression of lymphoid homing receptors such as CD62L and CCR 
(Callan et al. , 1998; Catalina et al. , 2002; Williams et aI. , 2004). This is the typical
phenotype of most activated virus-specific T cells , an indication that they are primed and
able to survey peripheral tissues for the presence of antigen. Studies have demonstrated
that activated EBV -specific T cells have immediate effector functions using ex vivo
cytotoxicity assays and intracellular stains for perf orin, IFNy and MIP- 1 P (Callan et al.
2000; Catalina et al. , 2002). The phenotype and function of activated EBV -specific T
cells will be important for comparison to the phenotype and function of memory T cells
during this acute infection in order to assess whether any productive cross-reactive
interactions have occurred.
I. Infectious mononucleosis
Two qualities of the primary immune response to EBV that make it somewhat
unusual compared to that directed at other viruses are the extent of immune activation
and the large magnitude of the T cell response, both of which are thought to contribute to
the age-related T cell-mediated pathology known as infectious mononucleosis (1M)
(Silins et al. , 2001; Willams et al. , 2004). Primary EBV infection during childhood is
often sub-clinical and goes unnoticed. Therefore, little is known about the kiJ;etics and
specificity of the primary immune response to a childhood infection. Alternatively,
primary EBV infection during adolescence frequently presents as 1M. EBV -associated
1M is confirmed by a serological test for the presence of viral capsid antigen-specific IgM
antibody, and patients typically present with fever, pharyngitis and lymphadenopathy;
Splenomegaly and hepatomegaly can occur, but are often missed in the absence of
ultrasound examination (Ebell, 2004). Older adults with acute EBV infection more
commonly have complications associated with 1M , including hepatomegaly, jaundice and
even fulminant hepatitis (Auwaerter, 1999; Ebell , 2004).
1M is an immune-mediated pathology, the symptoms of which have been
attributed to the hyperexpansion of activated CD8 T cells (lymphocytosis) that secrete a
variety of inflammatory and antiviral cytokines , likely contributing to the elevated levels
of IL- , IL- , TNFa, IFNy and MIP- l P previously detected in patient sera and tonsils
(Foss et al. , 1994; Iwatsuki et al. , 2004; Nakayama et al. , 2004). One of the criteria for
1M diagnosis is the presence of at least 50% lymphocytes and at least 10% atypical
lymphocytes in the peripheral blood, of which the majority are EBV-specific CD8 T cells
(Ebell, 2004; Wood and Frenkel, 1967). The degree of lymphoproliferation and the
extent of immune activation, marked by the prolonged expression of CD244 on CD8 T
cells, have both correlated with the presence and severity of 1M symptoms (Silins et aI.
2001; Willams et al., 2004). CD244, or 2B4, is a component of the SAP/SLAM
lymphocyte activation pathway and its expression has correlated with the acquisition ofT
cell effector functions, such as granyme Band perforin expression and rapid .IFNy
production (Speiser et aI. , 2001). It is stil unclear what causes such a high degree of
lymphoproliferation and immune activation durng the acute EBV response. Two
possible explanations put forth in the field are 1) a high viral load and 2) the additional
activation of memory CD8 T cells, either through a TCR-mediated or bystapder
mechanism (Rickinson and Kieff, 2001; Rickinson and Moss, 1997; Silins et al. , 2001).
Evidence against the idea that a high viral load is the cause of the exaggerated T cell
response includes a study showing similar levels of virus in asymptomatic and
symptomatic individuals during acute EBV infection and at least two studies
demonstrating that antiviral drugs , such as acyclovir, reduced viral load but had no affect
on the symptoms of 1M (Andersson et al. , 1987; Torre and Tambini, 1999). Thus , this
thesis research is designed to test the theory that EBV -induces the activation of cross-
reactive memory CD8 T cells through a TCR-mediated mechanism.
J. CDS T cell response to persistent EBV infection
Although EBV establishes a persistent infection, the massive CD8 T cell response
typical in 1M patients is eventually downregulated during convalescence. Many T cells
are deleted, but some survive and form a "memory" T cell population, which appears
necessary to keep the virus under control by preventing or suppressing a productive re-
activation of viral replication (Rickinson and Kieff, 2001). The frequency of CD8 T cells
specific to anyone EBV -derived epitope may still constitute a large proportion of the
total memory T cell pool, comprising up to 5.5% of CD8 T cells in the peripheral blood
as determined with MHC Class I tetramers (Callan, 2003). The frequency range of
memory T cells specific for the known HLA-A2-restricted epitopes are presented in
Table Early comparisons of the primary and memory CD8 T cell responses of
individual patients revealed differences in the relative frequencies of each epitope-
specific response during these two distinct phases ofthe immune response. For instance
one study reported that the response to immunodominant epitopes was more extensively
downregulated than that to subdominant epitopes during the contraction phase of the
primary T cell response, resulting in an altered epitope hierarchy in memory (Steven et
al. , 1996). However, there were many caveats associated with this study, which relied on
in vitro stimulated T cell lines and limiting dilution assays that may not equally support
the growth of all T cell clones and which did not assess T cell reactivity to lytic epitopes.
A more recent comparison of the clonal composition of primary and memory EBV-
specific responses used ex vivo tetramer+ T cell populations and monoclonal antibodies
to assess their Vp usage, which more accurately demonstrated that the most dominant
Vp-specific T cell populations, of the two epitope-specific responses examined, were
heavily culled during the establishment of memory (Callan et al. , 2000). While the same
dominant epitope-specific , Vp-defined, T cell clones were detected in the memory T cell
pool, they were present at lower frequencies. It has been postulated that the extent of
downregulation of an epitope-specific T cell response has to do with the limited lifespan
of the T cell clones comprising that response, a concept referred to as T cell senescence
(Davenport et al. , 2002). According to this theory, a higher rate ofT cell proliferation, as
is associated with immunodominant responses, will cause a lower rate of T cell survival
into memory. This concept offers one explanation for why T cell responses to latent
epitopes are often more pronounced in the memory phase because they are often
sub dominant to the T cell responses directed at lytic epitopes during the primary phase
and, therefore, undergo less proliferation during that time . (Callan, 2003; Callan et al.
1998; Catalina et al. , 2001). While an intriguing theory, this clearly does not appear to
occur during well-characterized non-persistent infections, such as LCMV-Arstrong,
where the epitope-specific hierarchy present during the acute phase of the infection is
maintained into memory. Thus if the theory holds true, T cell senescence may more
often be associated with persistent viral infections, where antigen concentrations remain
high or increase periodically during episodes of viral replication.
K. Features of the EBV(BMLFl)-specifc TCR repertoire
The T cell response to the early lytic epitope EBV-BMLFb80-288 is often
immunodominant during the primar phase of the immune response (Table 1). The TCR
repertoire that recognizes BMLF1 , among all other known EBV-derived epitopes , has
been the best characterized and has been described as oligo clonal. However, this
repertoire has characteristics of both a diverse and a restricted repertoire. The repertoire
is diverse for two reasons: 1) the dominant Vp family, as well as the clonotypic
composition of that family, varies between individuals and can be referred to as the
private specificity of the BMLF1-specific repertoire, and 2) multiple sub dominant Vp
families are often used by each individual (Anels et al. , 2000; Callan et al. , 2000; Lim et
al. , 2000). These observations imply that multiple different TCR structures can interact
with BMLF1. There are also two features of this repertoire that restrict it: 1) despite
individual variation in the combination of Vp families used, each individual's repertoire
often includes one or more of 4 common Vp families (VP2 , 4, 16 , 22) and 1-2 common
Va families (Va2. , 15), which can be referred to as the public specificity of the
BMLF1-specific repertoire, and 2) each Vp family is frequently comprised of very few
clones (Anels et al. , 2000; Callan et al. , 2000; Cohen et al. , 2002; Lim et al. , 2000). One
of the most conserved elements of the BMLF1-specific TCR repertoire is the usage of
Va15 because it can pair with 3 of the 4 common Vp families , suggesting that the a-
chain may contribute more than the p-chain to the interaction with BMLF1 (Lim et al.
2000). Clones expressing Va15 have conserved, usually germline encoded, CDR3a
motifs that vary depending on which V family is expressed (Anels et aI. , 2000; Lim et
al. , 2000). Each of four frequently expressed Vp families (VP2, 4, 16 , 22) is commonly
associated with a particular Jp family and uses a conserved CDR3p motif, which often
includes non-germline encoded N-additions (Table 2) (Anels et al. , 2000; Lim et al.
2000). The one outstanding feature of these BMLF1-specific CDR3p motifs was the
presence of one or more glycine residues, however, the significance of this is unclear
(Anels et al. , 2000; Cohen et al. , 2002; Lim et al. , 2000).
Analyses of the ex vivo BMLF1-specific TCR repertoire have demonstrated that
while the clonal composition of given Vp family appeared stable over time, the V
hierarchy changed during the establishment of memory, resulting in a decreased
proportion of T cells expressing a Vp family that once dominated the primary epitope-
specific response (Callan et al. , 2000). One interpretation of these data is that the
dominant Vp-specific response was heavily culled during the contraction phase of the
immune response, but not to the extent that it was completely deleted (Callan et al.
2000). T cell senescence is one possible explanation for this result since BMLF1 is
thought to be an immunodominant epitope during the acute phase of EBV infection and
the responding T cells are likely to proliferate extensively during this time, many of
which could reach the end of their finite lifespan (Davenport et al. , 2002). Alterations in
the clonal hierarchy of the BMLF1-specific response were only observed in one study,
which relied on the long-term in vitro proliferation ofT cells that can bias the results
Table 2. The public specificity of a BMLF1-specific TCR repertoire.
famil famil CDR3 uence Va famil Ja famil CDR3a se uence
SA-RD*TGNGY- TF varies AE- NARL-
SA- GVGNTI- YF
1.4 SV-GTGGTNEKL- varies AE-SIGKL-
varies AS-SQSPGGTQ- YF AE- YSSASKI-
AS- PGEL- VV-NGMDSSYKL-
This table was adapted from (Urn et aI. , 2000), and has been confirmed by data
reported in (Annels et aI. , 2000; Cohen et aI. , 2002). All V family nomenclature is
based on (Arden et aI. 1995), 9Ja nomenclature according to the
Immunogenetics database. Bolded residues are non-germline encoded, and
include the Op region in the case of COR3p.
(Anels et al. , 2000). However, one interesting finding came from that study, which was
that amino acids in positions 4 and 6 of the BMLF1 peptide sequence most likely make
contact with the TCR based on alanine substitution experiments and, overall, Vp22N a2+
T cell clones were more adaptable to variant BMLF1 peptide ligands than were other
clones, such as those expressing Vp2Na15 (Anels et al. , 2000).
L. Influenza A virus
The other virus-specific T cell response investigated in this thesis work was that
specific for influenza A virus (IV). Most of the world' s population has been infected
with IV by a young age and, therefore, have virus-specific memory CD8 T cells. This
gave us the opportunity to investigate the cross-reactive potential of a memory T cell
population that is shared among many different individuals with otherwise unique
histories of infection. Multiple studies investigating the presence of IV -specific memory
T cells have reported between 55-100% of adults have previously been exposed to IV
(Boon et al. , 2002; He et al. , 2003; Lalvani et al. , 1997). IV-specific memory T cells can
comprise 0.06- 6% of the CD8 T cell population found in the peripheral blood, as
determined by stimulating PBMC with either live virus (H3N2 , Resvir-9) or inactivated
allantoic fluid from infected eggs (H3N2 , Sydney and H1N1 , Beijing) and then staining
extracellularly for CD8 and intracellularly for the production of IFNy (Boon et. al. , 2002;
He et al. , 2003).
Although both are common human viruses, IV is very different from EBV.
Influenza A viruses represent one genera of the Orthomyxoviridae family (Wright and
Webster, 2001). Co-infection with multiple sub-tyes of IV promotes gene reassoi1ment
known as antigenic shift, and the emergence of new sub-types. IV sub-types are defined
by the HA and NA genes expressed by the virus. HA and NA are two of 10 known viral
proteins. They are found on the surface of the virion and are the major targets of the
humoral immune response. Hence these two proteins often undergo antigenic drift
where minor changes in' their immunogenicity allow certain virus strains to escape
detection by neutralizing antibodies. Thus, the existence of multiple sub-types and
strains, to which a host has insuffcient humoral immunity, leaves a host susceptible to
repeat, but non-persistent, infections with IV.
IV is spread via an aerosol route and, thus , the primary site of viral replication is
the respiratory tract, predominantly in the resident epithelial and mononuclear cells
(Wright and Webster, 2001). The incubation period is approximately 3 days , when there
is a peak in viral load, and virion shedding stops between days 6-8 post-infection.
Clinical signs and symptoms display tremendous variability, ranging from an
asymptomatic infection to death, and appear to depend heavily on the age of the
individual and the presence of any underlying medical conditions. The symptoms of an
uncomplicated infection include headache, fever, chils , cough, myalgia, and malaise, all
of which usually resolve within 1-2 weeks. Increased morbidity often occurs in the very
young (0:5 years of age) and the very old (/65 years of age), presumably due to the
absence or waning of pre-existing immunity to IV, and is commonly associated with
severe viral pneumonia.
M. Primary and memory CDS T cell responses to IV
Research on natural acute IV infection is lacking largely because patients are
rarely admitted to hospitals or visit outpatient clinics and, when they do , diagnostic tests
for IV are rarely performed. An increase in the number of CD8 T cells can be found in
the peripheral blood between days 6- 14 post-infection and returns to baseline between
days 21- , but the average frequencies and activation phenotype of epitope-specific T
cells during this phase of the immune response have not been extensively studied (Wright
and Webster, 2001).
Each IV infection is transient, and the cellular immune response likely contributes
to viral clearance. The CD8 T cell response is known to target almost all viral proteins:
, M1 , M2 , NS1 , NP , PB1 , and PB2 (Gotch et aI. , 1987; Jameson et al. , 1998; Man et
al. , 1995). M1 , or matrix protein, underlies the lipid bilayer of the virion. It is the most
abundant viral protein and is a target of the immunodominant response in most
individuals (Wright and Webster, 2001). The highly conserved sequence of M1 among
different viral sub-types and strains likely explains the maintenance of M1-specific
memory T cells over time (Boon et al. , 2002; Naumov et al. , 2003; Prevost-Blondel et al.
1997). In addition to the wide variety of epitopes derived from IV, a wide variety of
HLA alleles are used to present these epitopes to IV-specific CD8 T cells (Jameson et al.
1998). All individuals who express HLA-A*0201 use this allele to present IV-specific
peptides, however, there is evidence to suggest that HLA-B alleles , such as B*3501 and
B*2701 , often elicit a more dominant CD8 T cell response (Boon et aI. , 2004). HLA-
A*0201 molecules present an immunodominant epitope 66, and 78- 100% of
individuals expressing this allele are reported to have memory T cells specific for this
epitope (Bednarek et al. , 1991; Gotch et al. , 1987; Lalvani et aI. , 1997; Lawson et al.
2001; Lehner et al. , 1995; Pittet et al. , 2001). In memory, the frequency of Ml 66-
specific CD8 T cells varies among HLA-A2+ individuals, ranging from 1/250 000 to
1/2125 PBMC , and has been estimated to average 0. 13% of CD8 T cells in the blood
(Jameson et al. , 1998; Lalvani et al. , 1997; Lehner et al. , 1995; Pittet et al. , 2001; Prevost-
Blondel et al. , 1997). HLA-A *0201 molecules also present several other epitopes , which
are presumably subdominant due to the decreased ability to detect T cell responses
directed against these epitopes among individuals (Table 3). However, a cross-reactive
stimulation may result in the expansion of one of these otherwise sub dominant IV-
specific memory T cell populations , altering the resting-state epitope-specific hierarchy.
N. Features of the (IV)Ml-specific TCR repertoire
This thesis will focus on the TCR repertoire directed towards the
immunodominant, HLA-A2-presented, IV M1s8-66 epitope. Point mutations in the 
peptide initially determined that the central portion of the peptide was important for its
presentation and subsequent recognition by M1-specific CD8 T cells. Positions 4-6 were
thought to face the MHC Class I molecule, while positions 3, 7 and 8 of the peptide
sequence were thought to face the TCR (Gotch et aI. , 1988). Once the crystal structure of
the M1 :HLA-A2 complex was solved, it was evident that M1 was unusual in its lack of
prominent aa side chains directed towards the TCR (Madden et aI. , 1993). It is possible
that the unique structure of the M1 peptide in the context of HLA-A2 plays a role in the
selection of an immunodominant Ml-specific TCR structure, expressing Vp 17 /Jp2. 7 and
ValO.2/Ja42 and having the conserved CDR3 motif *RS* and a CDR3a loop that is
Table 3. HLA-A2-presented, IV-derived , epitopes and the frequency range
of CDS T cells specific for them.
% of A2+ Memory
pitope aa se uence Reference res onders T cell fre
GILGFVFTL (Gotch et aI. , 1987) 75-100% 1/250,000-1/2125 PBMC
r 0. 13% of COB T cells
M 1 ILGFVFTL TV (Gianfrani et aI., 2000) 67%
SLCPIRGWAI (Gianfrani et aI. , 2000) 17%
213 221 CVNGSCFTV (Wedemeyer et aI. , 2001)
N P 85- KLGEFYNQMM (Robbins et aI. , 1989)
NS1 122 13o AIMOKNIIL (Man et aI. , 1995) C:1/500 000 PBMC
FMYSOFHFI (Gianfrani et aI. , 2000) 33%
P A225-233 SLENFRA YV (Gianfrani et aI. , 2000) 33%
PB1 413-421 NMLSTVLGV (Gianfrani et aI. , 2000) 33%
* Percent of HLA-A2+ people in a resting memory state with T cells of this
specificity, + (Jameson et aI. , 1998; Lalvani et aI., 1997; Lawson et aI. , 2001;
Lehner et aI. , 1995; Pittet et aI., 2001; Prevost-Blondel et aI. , 1997), 0 (Jameson
et aI., 1998), NO: not sufficiently determined or not reported
extended by multiple glycine residues (Lawson et al. , 2001; Lehner et al. , 1995; Moss et
al., 1991; Naumov et al., 1998; Naumov et al., 2005; Stewart-Jones et al., 2003)
(Naumov et al. , manuscript in preparation).
The full crystal structure of this immunodominant TCR (JM22) bound to the
M 1 :HLA - A2 complex revealed some unusual characteristics of this interaction compared
to most of the 19 other structures solved to date (Stewart-Jones et al. , 2003). First, the
orientation of the TCR over the pMHC was more orthogonal than the typical diagonal
orientation of other known structures. The authors suggested that the CDRlp and
CDR2p regions of Vp 17 directed this orientation. Second, the interaction between the
TCR and pMHC is biased toward the TCR p-chain, providing 67% of the contact region
while other structures often use both chains equally or have an a-chain bias. The CDR3
loop is centered over the M1 peptide, and the authors suggest it is responsible for
providing the specificity for a high avidity interaction. While the a-chain provides no
hydrogen bonds to the interaction, it does make direct, but weak, contact with positions 4
and 5 of the M1 sequence and contributes to the overall stability of the complex. Third
due to the lack of prominent side chains at the interface, water molecules are forced to
make a vital contribution to the shape complementarity between the TCR and the pMHC.
Overall, it was reported that four key interactions conferred the specificity of the JM22
TCR for M1 :HLA- , and those interactions are diagramed in Figure 4 (Stewart-Jones
et al. , 2003).
Despite this dominant selection for TCRs expressing Vp17 and Va10. , the Ml-
specific TCR repertoire can still be described as polyclonal. Multiple Vp 17+ T cell
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clones exist, based on their unique nucleotide sequence, that encode the characteristic
*RS* CDR3p motif (Naumov et al. , 1998; Naumov et al. , 2005; Naumov et aI. , 2003).
There are also several Vp 17+ T cell clones that express alternative Jp families and thus
express variations in the length and sequence of the CDR3p loop (Naumov et al. , 2005;
Naumov et al. , 2003). Furthermore, some M1-specific T cell clones express alternative
and Va families, although these clones are present at much lower frequencies
(Lawson et al. , 2001; Naumov et al. , 2005) (Naumov et al. , manuscript in preparation).
By maintaining a vast distribution of M1-specific T cell clones, the majority of which
remain at a relatively low frequency, the immune system is better able to adapt to any
changes in the concentration and sequence of the M1 peptide ligand over time (Naumov
et al. , 2005; Naumov et al. , 2003).
o. Thesis objective
EBV has a large genome With the capacity to encode a multitude of T cell
epitopes simultaneously throughout the life of its host many of which could be
recognized by memory CD8 T cells specific for other pathogens. Furthermore, primary
EBV infection is frequently asymptomatic in children but in adolescents and young adults
infection often results in a T cell-mediated disease pathology known as infectious
mononucleosis , the clinical signs and symptoms of which can range from mild to severe.
Since exposure to pathogens generally increases with age, it is likely that adolescents and
young adults have a greater proportion of cfPss-reactive CD8 T cells in their memory T
cell pools than do children. Thus, our hypothesis was that cross-reactive memory CDS
T cells specific for previously encountered pathogens are activated during acute
EBV infection , and at these cross-reactive CDS T cell responses are, at least 
part, responsible for the development of infectious mononucleosis. My thesis work is
presented in three parts:
Chapter III: The identification of cross-reactive CD8 T cell responses involving EBV-
derived, HLA-A2-presented, epitopes.
Chapter IV: Cross-reactive CD8 T cells specific for EBV-BMLFb80-288 and IV-Mls8_
contribute to the lymphoproliferation in EBV -associated infectious
mononucleosis.
a. What is the frequency of this cross-reactive response among
individuals?
b. What are the effector functions that result from this cross-reactive
interaction?
c. Does this cross-reactive response correlate with the severity of 1M?
Chapter V: The clonal composition of the cross-reactive CD8 T cell response with
specificity for EBV-BMLFh80-288 and IV- 66: Features of a cross-
reactive TCR repertoire.
a. What is the structure(s) of this cross-reactive TCR and what features
distinguish it from a non-crossreactive TCR?
b. How is the cross-reactive repertoire organized? Does it have features
of a public or private repertoire? Is it comprised of a narrow or broad
collection of cross-reactive clones?
Increased disease severity among young adult and adult populations compared to
children has been observed following infection with EBV and other human viruses, such
as measles , mumps, and varicella-zoster viruses. In addition to age, there are many
factors that can contribute to variations in disease severity, including genetics , virus strain
and infecting dose, and the presence of underlying medical conditions that cause an
immunocompromised state. This thesis examines the influence of an individual's history
of infection and, in particular, cross-reactive memory CD8 T cell responses on the
development and severity of infectious mononucleosis associated with EBV infection.
CHAPTER II:
MATERIALS AND METHODS
A. Human subjects
Influenza A virus-immune patients with acute EBV infection were between the
ages of 18-23 and were volunteers from the University of Massachusetts (UMass)
Student Health Services at Amerst, MA. HLA-typing was performed using the
Lymphotype Class I system (Biotest Diagnostics, Denvile, NJ) and an Olerup SSP kit
(Geno Vision, West Chester, P A). Acute EBV infection was confirmed by a monospot
test and the detection of capsid-specific IgM in patient sera. Positive staining with HLA-
A2-tetramers loaded with influenza-Ml was used as an indication that these individuals
had been exposed to influenza A virus in the past. Patients provided up to eight blood
samples (50 ml each) starting at presentation with 1M (Day 0), then weekly for the
following 6 weeks, and then again at 1 year. When possible , the severity of the clinical
signs and symptoms of 1M at the time of the visit were graded on a scale of 1 (mild) to 5
(severe).
Healthy donors between the ages of 24-60 were volunteers from the research
community at UMass Medical School (Worcester, MA). HLA status and immunity to
EBV and influenza A virus were assessed using monoclonal antibody (BB7. , Becton
Dickinson, San Diego , CA) and tetramer stains , respectively. Previous exposure to EBV
was confirmed by the detection of capsid-specific IgG in donor sera. Donors provided up
to three blood samples (60 ml each). This study was approved by the Human Studies
Committee at UMass Medical School.
B. PBMC isolation
Whole blood was diluted 1:2 with Hank' s balanced salt solution (Gibco , Carlsbad
CA) and 20-25 ml was layered over 15 ml of Ficoll-Paque Plus (Amersham Bioscience
Uppsala, Sweden) and subsequently spun at 360 g for 30 min with no brake. The PBMC
layer was washed three times with the Hank' s solution, spun for 10 min with brake, first
at 320 gand then at 240 g for all subsequent spins.
C. CDS T cell isolation
PBMC were passed through nylon mesh, counted, and resuspended in magnet
buffer before they were stained with anti-CD8 microbeads (Miltenyi Biotech, Auburn
CA) according to the manufacturer s recommendation. Positive selection of CD8+
lymphocytes was performed using the Miltenyi Biotech MACS system.
D. CDS T cellUne cultivation
T2 cells (ATCC #CRL- 1992) served as the antigen presenting cells after being
pulsed with 1 J.M of peptide for a minimum of 3 hours at 37 C, irradiated with 3000
, and washed of free peptide. CD8+ lymphocytes were plated at 2.5 x 10 per ml
together with the T2 cells at 5 x 10 per ml in 4 ml total volume per well of a 12-well
plate. T cell lines were fed media (AIM-V (Gibco) supplemented with 14% human AB
serum (Nabi, Miami , FL or Gemini , Woodland, CA), 16% MLA- 144 supernatant (Rabin
et al., 1981), 10 U/ml rIL-2 (Becton Dickinson), 1% L-glutamine (Gibco), 0.5% p-
mercaptoethanol (Sigma, St Louis , MO), 1% HEPES (Hyclone , Logan, UT)) every 3-
days and were re-stimulated with fresh T2 cells weekly.
E. Peptides
The following peptides were synthesized to ::90% purity by Biosource
(Camarillo CA): EBV-BMLF1 80-288 (GLCTL V AML),
(YVLDHLIVV),
EBV - LMP2329 337
(LL WTL VVLL), EBV-BRLF110 117 EBV - EBNA3As96 604
(SVRDRLARL), IV-M1s 66 (GILGFVFTL), IV-NP8s-94 (KLGEFYNQMM), tyrosinase
(YMGTMSQV), HIV -gag778S (SL YNTV ATL). Peptide stocks used to pulse T2 cells
were kept at 0. 1 mg/ml in sterile water. Peptide stocks used for stimulation in
intracellular assays were kept at 1 mg/ml in DMSO.
F. Tetramers
A detailed description of the protocol used by the tetramer facility at UMass
Medical School has been previously published (Catalina et al. , 2001). Tetramers were
assembled using the above peptide sequences for EBV-BMLF1 and influenza-M1 and
were conjugated to phycoerythrn (Sigma), allophycocyanin (Caltag, Burlingame, CA),
or Quantum Red (Sigma). Tetramers assembled with HIV -gag or tyrosinase
(Imunomics , San Diego , CA) were used as negative controls, and non-specific staining
was never observed.
G. Extracellular staining
Freshly isolated or cultured T cells were plated at 10 per well and washed with
FACS buffer (PBS , 2% FCS, 1% sodium azide). Tetramers were incubated at room
temperature for a total of 40 min. In experiments where cells were co-stained with
tetramers and additional surface markers , T cells were pre-incubated with tetramers for
20 min then allowed to incubate with all other antibodies for an additional 20 min at
room temperature. Ce ls were washed and fixed with F ACS Lysing Solution (Becton
Dickinson), incubating at room temperature for 5 min before finally being resuspended in
F ACS buffer. All TCR Vp-specific antibodies were purchased from Imunotech
(Marseille Cedex, France) and all other antibodies were purchased from Becton
Dickinson. A F ACS Calibur (Becton Dickinson) was used for most data acquisition, and
all data analysis was completed using Flowjo software (Tree Star Inc. , Ashland, OR). In
cases where T cells could co-stain with more than one tetramer or antibody, fluorescence
compensation was attained using single-color control samples prior to data acquisition to
ensure that co-staining was specific and not the result of the fluorescence of one
fluorochrome bleeding into the improper channel of the F ACS Calibur. Under
circumstances where fluorescence compensation could not be attained, co-staining was
not assessed, and this has been noted in the applicable figures.
The total number of antigen-specific CD8 T cells per ml of blood was determined
using the following calculation: (ex vivo % of tetramer+ cells/CD8) x (ex vivo % 
CD8+ cells/PBMC) x (total number of PBMC isolated from the blood) divided by the
total volume (ml) of blood prepared.
H. Intracellular staining
Except in peptide titration experiments where the concentration varied, T cells
incubated with a standard 5 M concentration of peptide in media for 5 hours at 37 Oc in 
the presence of brefeldin A. When combined with extracellular staining, the same
peptide stimulation protocol was used and T cells were then washed in F ACS buffer and
stained with tetramer for a total of 40 min at room temperature. T cells were washed and
then fixed and permeaqilized using Cytofix/Cytoperm (Becton Dickinson) according to
the manufacturer s instructions. The following monoclonal antibodies were used: anti-
IFNy (0.2 /lg clone B27 , Becton Dickinson), anti-MIP- (0.2 /lg clone D21- 1351
Becton Dickinson), and anti-TNFa (mAb11 , eBioscience). The appropriate isotype
control antibodies did not stain positive. Data acquisition and analyses were performed
as described above.
I. CDS T cell sorting
Freshly isolated or cultured T cells were stained extracellularly as described
above using 2% FCS/PBS. T cell populations were sorted using the Mo-Flo cell sorter
(DakoCytomation, Carinteria, CA) and collected in T cell line media. Single T cells
were sorted using a FACS Vantage (Becton Dickinson) and collected in 96-well plates
containing feeder cells and T cell line media.
J. Short-term CDS T cell cloning
Double tetramer-positive T cells were sorted at 1 cell per well of a 96-well plate.
In addition, each well contained 10s irradiated donor-specific CD4+ T cell blasts and 2 
of a 1: 1 mixture of irradiated T2 cells pulsed with BMLF1 or M1 peptides. Clones
were fed fresh media every 3-4 days, re-stimulated with T2 cells at day 7 , and their
specificity tested on day 14.
K. Chromium release assay
K562 (Britten et al. , 2002) and cos-7 cell lines stably transfected with HLA-A2.
both worked as target cells , pulsed with 100 /lM of peptide for 1 hour at 37 oC and then
for an additional hour with 100 /lCi Sl Cr per 10 cells. Target cells were washed three
times and plated at 5 x 10 per well of a 96-well plate. Day 14 T cell clones were tested
using split-well analysis; 30 l of each clone were loaded per well per target cell type.
Spontaneous Cr release was measured upon incubating target cells with 30 l of
irradiated feeder cells alone, which were cultured in parallel with the T cell clones for use
as negative control cultures. Plates incubated 8 hours at 37 and the supernatants were
harvested and counted using a MicroBeta TriLux scintilation counter (Perkin Elmer
Wellesley, MA). Any experimental value greater than three standard deviations above
the average spontaneous release value was considered a positive result.
L. IFNy ELIspot assay
Our protocol was adapted from a previously published method (Britten et al.
2002) using Mabtech (Mariemont, OH) reagents. Briefly, primary anti-IFNy (mAb 1-
D1K) was loaded onto Multiscreen-IP fiter plates (Milipore, Billerica, MA) at 10 g/ml
and incubated overnight at 4 C. The plates were then washed and blocked with 10%
FCS/RMI for 1 hour at 37 OC. K562/HLA-A2. 1 or cos-7/HLA-A2. 1 cell lines served as
the antigen-presenting cells (APC), pulsed with 50 M of peptide for 3 hours at 37 
and washed of free peptide. Thes APCs were loaded at 10 per well. Day 14 T cell
clones were tested using split-well analysis , whereby 5 l of each clone were loaded per
well per APC type. Negative control wells consisted of APCs plus 5 l of irradiated
feeder cells alone, which were cultured in parallel with the T cell clones. Plates
incubated at 37 oC for 20 hours , were washed, and loaded with 2 g/ml of the secondary,
biotinylated, anti-IFNy (mAb 7-B6- 1). Following a 3 hour incubation at room
temperature, plates were washed and loaded with streptavidin-horseradish peroxidase
diluted 1: 1 00 , and incubated for 2 more hours at room temperature. Nova Red Substrate
(Vector Labs , Burlingame, CA) was added to the plates according to the manufacturer
instructions and incubated for 40 min at room temperature. Plates were washed and left
to air dry before being read manually. Negative control wells resulted in no detectable
spot-forming units, therefore, any well having greater than 5 spot-forming units was
considered positive.
M. RNA isolation and cDNA synthesis
When available, RNA was isolated from at least 10 T cells using TRIol reagent
(Invitrogen, Carlsbad, CA) according to the manufacturer s recommendation. Using 0.
1 f.g of RNA, cDNA synthesis was performed with the following reaction: 2 f.M poly- 
(Integrated DNA Technologies , Coralville, IA), IX RT buffer (Invitrogen), 2.5 mM DTT
(Invitrogen), 40 mM dNTPs (Promega, Madison, WI), 15U RNAguard (Amersham
Bioscience) heated to 65 o for 5 min and placed on ice. Superscript III reverse
transcriptase (Invitrogen) was added at 100U per reaction (total volume per reaction was
20 f.l) and heated to 50 oc for 50 min before it was inactivated at 85 oC for 5 min.
N. CDR3 spectratyping
The TCR V gene nomenclature used throughout this thesis was based on that
reported by (Arden et al. , 1995). The cDNA was amplified with 1.6 f.M each of V- and
C-specific primers (Han et aI. , 1999; Maslanka et al. , 1995), IX PCR buffer II (Applied
Biosystems , Framingham, MA), 1.5 mM MgCh (Applied Biosystems), 40 mM dNTPs
(Promega), and 1 U AmpliTaq DNA polymerase (Applied Biosystems) in a 25 f.l volume
per reaction. The cycling program was the following: 94 oc for 30 sec, 55 Oc for 30 sec
72 for 30 see for a t tal of 30 cycles , followed by a 10 min incubation at 72 C. PCR
products (10 Ill) were then boiled for 3 min with formamide dye and were subsequently
put on ice. Samples were then loaded onto a 5% polyacrylamide gel and run at 2500V.
Gels were read by a FluorImager 595 (Molecular Dynamics , Sunnyvale, CA) and were
analyzed using ImageQuant softare (Molecular Dynamics).
o. TCR sub-cloning and sequencing CDR3 regions
Fresh PCR products (1-3 Ill) from the reaction described above were ligated into
the pCR4-TOPO vector (Invitrogen), which was used to transform TOP10 chemically
competent cells (Invitrogen) according to the manufacturer s protocol. Individual
colonies were picked for overnight 4 ml cultures. DNA was isolated with QIAprep
miniprep kits (Qiagen, Valencia, CA) and the CDR3 regions were sequenced at the
UMass Nucleic Acid Facility (Worcester, MA) using universal primers. Sequencing data
was analyzed using EditSeq software (DNAST AR Inc. , Madison, WI).
P. EBV quantification
Following the positive selection of PBMC samples for CD8+ lymphocytes, the
negative fractions were used for EBV quantification. An extracellular stain for CD3-
CD 19+ cells gave us an estimate for the total number of B cells in each sample. Samples
were digested and the DNA was isolated using a DNeasy Tissue kit (Qiagen). Each
sample was normalized to contain the DNA of 10 total B cells. Samples were run in
triplicate using the recommended protocol accompanying a LightCyc1er EBV
quantification kit (Roche , Penzberg, Germany). An internal positive control was supplied
with this kit.
CHAPTER III:
THE IDENTIFICATION OF CROSS-REACTIVE CDS T CELL RESPONSES
INVOLVING EBV-DERIVED , HLA-A2-PRESENTED, EPITOPES
Cross-reactive CD8 T cells exist with specificity for different proteins encoded by
the same virus (Anderson et al. , 1992; Kuwano et al. , 1991), different serotypes of the
same virus (Mathew et al. , 1998; Mongkolsapaya et al. , 2003), as well as for unrelated
viruses (Brehm et al. , 2002; Nilges et .al. , 2003; Wedemeyer et al. , 2001). EBV has a
large genome that encodes at least 69 proteins and innumerable T cell epitopes. Thus , we
hypothesized that EBV infection induces multiple cross-reactive T cell responses, which
would include T cells specific for multiple EBV proteins and memory T cells specific for
a previously encountered virus. To identify cross-reactive responses, we grew CD8 T
cell lines and stimulated them with more than 30 known HLA-A2-presented epitopes
derived from EBV, IV, cytomegalovirus (CMV), human immunodeficiency virus (HIV),
hepatitis Band C viruses (HBV, HCV), vaccinia virus (VV), and some self-proteins , such
as tyrosinase and protein phosphatase. We used the accumulation of intracellular IFNy
following short-term stimulation with any peptide other than that used to culture the T
cell line as an indication of a potential cross-reactive response. This screening process
revealed several different cross-reactive specificities that were present in T cell lines
derived from more than one donor, all of which could potentially contribute to the
immune response directed toward EBV.
A. Putative cross-reactive T cell responses involving two different EBV proteins
i. Specifcity for BMLFh8o-288 and LMP2329 337
BMLFI (GLCTLV AML) is an early lytic viral protein, and 100% of HLA-A2+
individuals mount a CD8 T cell response against this particular epitope during the acute
phase of EBV infection (Table 1) (Catalina et al. , 2001). LMP2 (LLWTLVVLL) is a
latent viral protein, and this particular epitope is a much less frequent target of the EBV-
specific CD8 T cell response (Table 1) (Catalina et aI. , 2001). BMLFl-specific T cell
lines derived from two healthy donors produced IFNy in response to stimulation with
LMP2 peptide (20-26%), but not in response to tyrosinase or other non-specific
stimulations (0. 1 %) (Figure SA, C). Control T cell lines derived from the same two
donors produced little to no IFNy following LMP2 stimulation, further suggesting that the
T cell population responding to LMP2 was growing in response to BMLF I-pulsed T2
cells and not in response to T2 cells alone (Figure 6A, B). VIe later confirmed this cross-
reactive response by using a similar BMLF1-specific T cell line derived from donor D-
002 to assess the ability of these cross-reactive cells to simultaneously bind BMLF1
tetramer while producing IFNy to LMP2 stimulation. In this case, the majority of the
IFNy production to LMP2 was coming from the BMLF1 tetramer-positive population
(Figure 5B). These two epitopes are similar in sequence, sharing 5 of 9 aa residues.
Thus , molecular mimicry may be the mechanism behind this cross-reactive interaction
since three of the shared residues are at consecutive central positions (P4-6) along the
epitope sequence and are likely available for TCR engagement. However, it is interesting
to note that we were unable to cultivate an LMP2-specific T cell line from donor D-002.
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After 8 weeks of culturjng, only 4% of the CD8 T cells produced IFNy in response to
LMP2 and this line did not respond at all to BMLF1 stimulation, exemplifying the non-
reciprocal nature of CD8 T cell cross-reactivity (data not shown). Furthermore, BMLF1-
specific lines derived from other unrelated donors did not share this particular pattern of
cross-reactivity. T cellliries derived from only 2 out of 6 healthy immune donors and 0
out of 5 1M patients displayed evidence of a cross-reactive response involving the EBV-
derived BMLF1 and LMP2 epitopes.
ii. Specificity for BMLF1 288 and BRLFI I09 117
Like BMLFI (GLCTLVAML), BRLF1 (YVLDHLIVV) is a lytic viral protein
but with an immediate early expression profie. Both epitopes are frequent targets of the
primary and memory EBV -specific CD8 T cell responses (Hislop et al. , 2002) (Table 1).
These two epitopes have no sequence similarity, yet data we derived from three different
individuals suggested that T cells existed that could recognize both epitopes. The most
convincing evidence of this cross-reactive interaction was the ex vivo detection of CD8 T
cells that co-stained with both BMLF1- and BRLF1-loaded tetramers, corresponding to
3% of the CD8 T cell population found in the peripheral blood of a patient, E1232
undergoing a primary immune response to EBV and presenting with symptoms of
infectious mononucleosis (1M) (Figure 7 A). Such a staining profile was not evident
when this T cell population co-incubated with BMLF1- and (IV)M1-loaded tetramers
suggesting that the interaction was indeed antigen-specific. Cross-reactive T cells that
can co-stain with two distinct tetramers likely reflect a high avidity interaction with both
epitopes. However, we have also observed cases where cross-reactive T cells presumably
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had a higher avidity for one epitope over the other. For example, co-incubating freshly
isolated CD8 T cells derived from 1M patient E1205 with BMLF1- and BRLF1-loaded
tetramers did not result in double tetramer-positive cells. Rather, in the presence of
BRLF1- loaded tetramer, the percentage of BMLFI tetramer-positive cells declined to
6% compared to a frequency of 2. 1 % when in the presence of a non-specific (IV)Ml-
loaded tetramer (Figure 7B). The same trend was observed later during the acute phase
ofEBV infection, when the frequency ofBMLFl tetramer-positive cells declined to 0.4%
in the presence of BRLF I-loaded tetramer as opposed to a starting frequency of 1.1 % in
the presence of the non-specific M1-loaded tetramer (Figure 7C). This data suggested
that this population of cross-reactive T cells had a higher avidity for the BRLF1 epitope
than the BMLFI epitope so that under competitive conditions, these cells would
preferentially bind BRLF I-loaded tetramer. Thus, this particular pattern of cross-
reactivity can be subtle but may frequently occur during the acute phase of EBV infection
since ex vivo tetramer staining indicated that 2 out of 4 1M patients mounted this cross-
reactive T cell response.
In an attempt to culture cross-reactive cells specific for BMLF1 and BRLFl , we
grew T cells isolated from healthy donor D-002 in the presence ofa 1:1 mixture of
BMLF1- and BRLF1-pulsed T2 cells. These conditions supported the growth of cross-
reactive cells that dimly stained BMLF1 tetramer, once again suggestive of a lower
avidity interaction with BMLF1 , while producing IFNy specifically to BRLFI stimulation
(Figure 7D). We were unable to detect this cross-reactive T cell response in 4 other
healthy donors but, in those cases, only BMLF1-pulsed T2 cells were used for T cell
culturing and that, presuplably low avidity, TCR stimulation may not have been sufficient
to support the growth of this specific cross-reactive T cell population.
B. Putative cross-reactive T cell responses involving two unrelated viruses, EBV
and IV
i. Specifcity for BMLF1 28o 288 and Mls8-
The immunodominant M1 epitope (GILGFVFTL) is a target of the IV-specific
CD8 T cell response within most HLA-A2+ individuals and shares only 3 of 9 aa
residues with the immunodominant BMLFI epitope (GLCTLV AML) derived from EBV
(Tables 1 , 3). Using both BMLF1- and M1-specific T cell lines, we have been able to
demonstrate the production of IFNy in response to stimulation with the opposite peptide.
As examples, 6% of a BMLF1-specific T cell line derived from healthy donor D-042
produced IFNy following M1 stimulation, while 3% of an Ml-specific T cell line derived
from healthy donor D-002 produced IFNy following BMLF1 stimulation (Figure 8A, B).
Control T cell lines derived from each donor and grown in the presence of T2 cells alone
did not produce IFNy following M1 (0.2%) or BMLF1 (0.3%) stimulation respectively
(Figure 6 F, A). Furthermore, using T cells isolated from donor D-042 , we cultivated a
second EBV-specific line using T2 cells pulsed with an LMP2 6 peptide (66% of the line
was specific based on IFNy production) and showed that the cross-reactive M1-specific
response was not present (0. 1 % produced IFNy to M1) (data not shown). Therefore, we
deduced that M1-specific T cells grew specifically to the BMLF1-pulsed T2 cells (Figure
8A).
We demonstrated the simultaneous recognition of (EBV) BMLF1 and (IV) M1
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using a combination tetramer and intracellular IFNy stain. Within an M1-specific T cell
line derived from 1M patient Ell01 , 2% of the cells produced IFNy following BMLF1
stimulation while simultaneously binding M1 tetramer with a range of intensities (Figure
8C). In the opposite stain, the same T cell line contained a smaller population of cells
(0.7%) that bound BMLFI tetramer while simultaneously producing IFNy to 
stimulation (Figure 8C). Overall , we were able to detect T cells with this cross-reactive
specificity within T cell lines derived from 3 out of 8 healthy immune donors. We were
also able to detect these cross-reactive T cells in the blood of 2 out of 8 1M patients
which will be further discussed in Chapter IV of this thesis.
ii. Specifcity for BMLFhso-2ss and NPS5-
NP (KLGEFYNQMM) is a sub dominant IV -derived epitope among HLA-A2+
individuals, with an aa sequence dissimilar from that of the immundominant EBV-
derived BMLF1 epitope (GLCTLVAML) (Tables 1 , 3). BMLF I-specific cell lines
derived from two different 1M patients had a small population of T cells (2%) that
produced IFNy in response to NP stimulation (Figure 9A, B). Control T cell lines derived
from the same two donors did not contain this subset ofNP-responsive cells (0. 3%),
suggesting that their growth was due to the presence of BMLF1 peptide in the culture
(Figure 6D , E). In patient Ell09 , we were able to confirm that this 2% subset ofNP-
responsive cells was able to bind BMLF1 tetramer, providing more definitive evidence
that these T cells could engage both of these structurally dissimilar epitopes (Figure 9C).
It is interesting that we were only able to culture T cells with this cross-reactive
specificity from the blood oflM patients (2 out of 4) and not from the blood of7 different
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healthy immune donors: As mentioned, the NP-specific T cell response is thought to be
subdominant. Since very little is known about the primary T cell response to a natural
human IV infection, the definition of subdominant is based mostly on the fact that it has
been diffcult to detect NP-specific memory T cells in healthy immune donors. The fact
that we were only able to detect these otherwise low frequency T cells in 1M patients may
indicate that some NP-specific memory T cells have proliferated and increased in number
in vivo as a result of cross-reactive stimulation with BMLFI and possibly other EBV-
derived epitopes. This hypothesis will require further investigation.
ii. Specificity for EBNA 3A 604 and s8~
We also have preliminary evidence to suggest cross-reactive T cell specificity for
an EBV epitope other than BMLFI. EBNA 3A is a latent EBV protein and a frequent
target of the CD8 T cell response, particularly during the persistent phase of EBV
infection (Catalina et al. , 2001). The EBNA 3A epitope (SVRDRLAR) shares only 1 of
9 aa residues with the immunodominant IV-derived M1 epitope (GILGFVFTL) (Tables
3), however, the M1-specific T cell lines derived from three separate healthy donors all
produced IFNy in response to EBNA 3A stimulation (Figure 10). This cross-reactive T
cell subset sometimes represented only a small proportion of the T cell line (D-012 , 4%
and D-046 , 2%) but sometimes included over half of the T cell population within that line
(D-002, 56%). Such an extensive population of EBNA 3A-responsive cells was not
observed in the control T cell line derived from D-002 (0.6%), and was absent from the
control T cell lines derived from donors D-012 and D-046 (Figure 6A-C).
cross-reactive response involving EBNA 3A would result in a second
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opportunity to reactiva e M1-specific memory cells and would do so during a different
phase of the virallifecyc1e, as BMLF1 is expressed during the lytic phase and EBNA 3A
is expressed during the latent phase. We detected the cross-reactive T cell response
specific for EBNA 3A and M1 in T cell lines derived from 3 out of 8 healthy immune
donors. This was the same frequency with which we detected the cross-reactive T cell
response specific for BMLF1 and M1 , and 2 of the 3 responding donors displayed
evidence of having both cross-reactive patterns. However, this cross-reactive response
has not yet been detected in T cell lines derived from 1M patients.
C. The individual variation in cross-reactive specifcities and the non-reciprocal
pattern of cross-reactive T cell responses
All of the EBV seropositive HLA-A2+ individuals enrolled in our study have had
a BMLF1-specific T cell population, but the presence of a cross-reactive subset within
that population, as well as the alternative specificity of those cross-reactive cells, varied
between individuals. This observation may reflect the clonal diversity of the BMLF1-
specific population and, therefore, the private specificity- of each individual's TCR
repertoire. Furthermore, any factors that affect antigen presentation will inevitably
influence the activation and magnitude of a cross-reactive T cell response. The
expression pattern of viral proteins and epitope processing affect the time, location, and
concentration of antigen presented to T cells. If the presentation of an alternative epitope
is less than optimal, it may prevent the development of a cross-reactive response in vivo.
Consequently, any cross-reactive T cell clones present at relatively low frequency in vivo
can be easily diluted out in bulk culture by the growth of more frequent, perhaps non-
crossreactive, T cell clones.
Through the study of cultured T cell lines, we have also observed non-reciprocal
or unequal patterns of cross-reactive responses. In the case of cross-reactive responses
involving BMLF1 and Ml , we often found that the frequency of cells producing IFNy in
response to a cross-reactive stimulation was higher in M1-specific T cell lines (3%) than
in BMLF1-specific T cell lines (1 %) (Figure llA, B). The difference between T cell
lines in the detection of cross-reactiveT cells was even more pronounced in a separate
experiment when we assessed another effector function, MIP- 1 P production. In this case
the frequency of cross-reactive cells in the M1-specific T cell line increased to at least
16%, but cross-reactive cells were undetectable in the BMLF1-specific T cell line using
this assay (Figure 11A, B). While it is stil unclear if these unequal patterns of cross-
reactivity wil hold true with T cells having other specificities , the non-reciprocal nature
of T cell cross-reactivity has previously been observed. Using murine models of
heterologous virus infection, the sequence of infections was determined to influence
protective immunity (Selin et al., 1998). For instance, LCMV -immune mice were
protected against a lethal VV infection, and subsets of LCMV -specific memory T cells
proliferated (ie. increased in number) following stimulation with VV; however, VV-
immune mice were not protected from LCMV infection, and VV -specific memory T cells
did not proliferate following stimulation with LCMV (Kim et al. , 2002). Since that
observation, it has also become apparent that cross-reactive T cell clones , based on
cytokine production, proliferate with different effciencies in vivo and that this may be
attrbuted to differences in TCR avidity for the alternative epitope
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(Comberg et aI. , 2005b). Thus , the stimulating antigen used to culture cross-reactive T
cell populations may only promote the outgrowth of a select subset of cross-reactive
clones having high avidity for that antigen.
D. Avidity ofthe cross-reactive TCR interaction with alternative epitopes
As mentioned above, a difference in avidity for the two epitopes may explain the
unequal patterns of cross-reactive T cell responses we have observed in cultured T cell
lines. To assess and compare the avidity of the interaction between cross-reactive T cells
and the M1 or the BMLF1 epitope , we used a decreasing titration of peptide in a standard
intracellular IFNy assay. The cross-reactive population within the M1-specific T cell
line, derived from healthy donor D-002, had a relatively similar avidity for Ml and
BMLF1 peptide, reaching half the maximumIFNy production between 10- M (BMLFl)
and 5x10- M (M1) (Figure 12A). In contrast, the cross-reactive population within the
BMLFl-specific T cell line, derived from the same donor, had at least a 100-fold higher
avidity for the Ml peptide, the alternative ligand, over the BMLFI peptide, reaching half
the maximum IFNy production at a 10- concentration of M1 and at a 5xlO-7 M
concentration ofBMLFl (Figure 12B). These data imply that culturing CD8 T cells with
BMLFI peptide selects for a smaller population of cross-reactive cells with very high
avidity for the alternative epitope, Ml , while culturing CD8 T cells with M1 peptide
promotes the outgrowth of a larger population of cross-reactive cells with an equal or 
slightly lower avidity for the alternative epitope, BMLFI. The reason for this may stem
from the structure of each epitope and its influence on TCR repertoire development.
The M1 epitope is presented to the TCR in a rather featureless orientation that
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likely imposes strict requirements on the structure of the TCR with which it interacts
namely VP17/Jp2.7/CDR3P *RS* , and it is reasonable to assume then that the interaction
is of relatively high avidity (Stewart-Jones et al. , 2003). If that strict Ml-specific TCR
structure, which comprises the bulk of the M1-specific repertoire, is also capable of
interacting with BMLF1 then it is not surprising that the majority of an M1-specific T
cell line responds to BMLF1 at some level, such as ilustrated in Figure 11A. In fact
data presented in Chapter V of this thesis wil reveal that BMLF1-specific T cells can
express Vp 17, the dominant Vp 17+ clone found in healthy donor D-002 expressing
VP17/J 7/CDR3P IDGTA.
In contrast to the M1 epitope, the BMLFI epitope does not appear to impose such
strict TCR requirements, as will be discussed in Chapter V of this thesis. The BMLF 1-
specific repertoire includes a more diverse array of TCR structures that likely have a
diverse array of avidities for the BMLFI epitope, and those T cells expressing Vp 17
represent only a small proportion. Thus , it is likely that only a small proportion of the
BMLF1-specific repertoire will meet the strict requirements necessary for forming a
stable interaction with the M1 epitope. It is not completely clear why the small
population of T cells within a BMLF1-specific T cell line interact with the Ml epitope
with higher avidity than the M1-specific T cell line, but perhaps the comparison was not
valid. The M1-specific T ceil line is highly polyclonal and the relative avidity
measurement we observed represents the average avidity of all the M1-specific clones
within that line. In contrast, the cross-reactive M1-specific population within the
BMLF1-specific T cell line is likely to be oligoclonal because, despite coming from a
diverse array of BMLF1-specific TCR structures , most Vp families within this line are
comprised of only 1 or 2 unique clones. Thus, the ideal experiment comparing the
avidities of the non-crossreactive and cross-reactive TCR interaction with the Ml epitope
will require individual T cell clones.
E. Chapter III Summary
We predicted that the large EBV genome encodes many T cell epitopes that can
simultaneously activate primary T cells and pre-existing cross-reactive memory T cells in
an antigen-specific manner. In this study alone, we detected cross-reactive T cell
responses with five different specificities that involved EBV -derived antigens. Each of
these cross-reactive responses has the potential to participate in the collective immune
response to acute EBV infection. Part of our hypothesis was that the contribution of
these cross-reactive T cell responses to the immune response promoted the development
of immune-mediated pathology, such as infectious mononucleosis, because the symptoms
and clinical signs of 1M are thought to be caused by the tissue-infiltrating, EBV -specific
T cells and the cytokines they secrete (Rickinson and Kieff, 2001). We next aimed to
determine if these cross-reactive T cell responses contributed to the magnitude and
quality of the total EBV -specific T cell response and, therefore, to the severity of
infectious mononucleosis.
There is no dispute that the in vivo environment during an acute viral infection
cannot be mimicked in vitro. In order to determine the physiological relevance of the
cross-reactive responses we detected in T cell cultures, we next aimed to detect these
cells ex vivo , in blood samples donated by 1M patients. However, these in vitro studies
have revealed certain features of T cell cross-reactivity that one must consider when
attempting to detect cross-reactive T cells:
1) At least 4 of the 5 cross-reactive specificities reported here involved epitopes
with little to no sequence similarity. Molecular mimicry is just one form of T
cell cross-reaCtivity and, therefore, assays developed for screening cross-
reactive responses should not be limited to peptides having similar sequence.
2) When detecting cross-reactive T cell responses, multiple different assays must
be employed. While co-staining with two tetramers can result in a double-
positive cell population, cross-reactive cells may have different avidities for
each epitope and, under competitive conditions, may preferentially bind one
tetramer over the other. Functional assays can also be deceiving.
reported here that, within an Ml-specific T cell line, a higher frequency of T
cells produced MIP- 1 P than IFNy following cross-reactive stimulation with
BMLF1 peptide.
3) Despite having the same acute viral infection, and even having T cell memory
to the same previously encountered virus, the frequency and specificity of
cross-reactive T cell responses remains unique to each individual. Based on
the literature, this observation may be attributed to each individual' s unique
history of infections and their private repertoire of T cell clones.
CHAPTER IV:
CROSS-REACTIVE CDS T CELLS SPECIFIC FOR EBV-BMLF1 28o 288 AND IV-
Mls8-66 CONTRIBUTE TO THE LYMPHOPROLIFERATION IN EBV-
ASSOCIATED INFECTIOUS MONONUCLEOSIS
There is a high degree of individual variation in disease severity associated with
human virus infections, and age is one of many factors that can contribute to such
variation. Childhood infections with EBV are often sub-clinical , while the same infection
is frequently symptomatic in adolescents and adults and presents as infectious
mononucleosis. 1M can vary in duration, from a few weeks to 6 months, and the
symptoms can vary in severity (Rea et al. , 2001). Complications , such as pneumonia and
fulminant hepatitis, are more common in older adults and have been linked to the
infiltration of activated T cells and EBV -infected B cells into these tissues (Auwaerter
1999; Axelrod and Finestone, 1990; Rickinson and Kieff, 2001). When comparng 1M
and asymptomatic cases of acute EBV infection, Silins et al. found that the magnitude of
the CD8 T cell response, not viral load, correlated with the presence or absence of disease
(Silins et al. , 2001). Furthermore, treatment of 1M patients with anti-viral drugs, although
decreasing viral load, did not have any effect on the disease course (Andersson et al.
1987; Torre and Tambini, 1999). These data suggest that a massive CD8 T cell response
can be counterproductive and mediate the disease pathology. It is stil unclear why this
massive CD8 T cell proliferation occurs more frequently in older individuals.
Based on murine models of heterologous immunity which showed that T cells
specific to a previously encountered virus may enhance the immunopathology during a
second unrelated viru infection, and based on the increasing number of reports
documenting CD8 T cell cross-reactivity between viruses, we hypothesized that cross-
reactive memory T cells specific to previously encountered pathogens contributed to this
massive CD8 T cell proliferation during acute EBV infection (Brehm et al., 2002;
Mongkolsapaya et al. , 20'03; Nilges et al. , 2003; Selin et al. , 1994; Wedemeyer et al.
2001; Welsh et al. , 2004). In support of this , there is well-documented evidence that at
least a proportion of the CD8 T cells activated by EBV can have alternative specificities
for allogeneic MHC molecules, self-peptides, and bacterial antigens (Burrows et al.
1994; Misko et al., 1999; Strang and Rickinson, 1987; Tomkinson et al., 1989).
Furthermore, as presented in Chapter III of this thesis, our preliminary data revealed at
least five different cross-reactive T cell specificities with the potential to contribute to an
immune response to EBV. Here we present the results of a more thorough investigation
of one of those cross-reactive T cell specificities, that involving EBV -BMLF1 and IV-
Ml. We were able to further characterize this cross-reactive response in vitro using T
cell clones and multiple functional assays , and demonstrated the physiological relevance
of this response through the detection ofthese cross-reactive T cells in the blood of 2 out
of 8 1M patients, both of which had notably skewed M1-specific memory TCR
repertoires that were suggestive of cross-reactive T cell expansions. These data provide
more support for our hypothesis that cross-reactive T cell responses contribute to the
development and severity of EBV -associated infectious mononucleosis;
A. Maintenance of cross-reactive T cells in the memory pools of healthy donors
Using the previously mentioned intracellular IFNy assay to screen T cell lines for
cross-reactive responses , we observed that 3 out of 8 healthy donors (38%) with previous
exposure to EBV and IV had cross-reactive T cells with specificity for EBV-BMLF1 and
IV -M1 within their memory CD8 T cell population (Table 4). In an attempt to determine
the frequency ofthese cross-reactive T cells in the peripheral blood, we co-stained CD8 T
cells ex vivo with BMLF1- and M1-loaded tetramers. A population of double tetramer-
postive cells (0.01%) was detectable when 10 events were collected, confirming our
ability to culture them in vitro (Figure 13A). This frequency may be an underestimate
given the potential for cross-reactive T cells to have a higher avidity for one epitope over
the other (Figure 7). Using this technique, we also demonstrated that the resting state
frequency of BMLF1- and M1-specific memory T cell populations, which would include
any cells with cross-reactive potential, were relatively stable over time (Figure 13B).
B. Breadth and quality of this cross-reactive T cell response
Further investigation into the effector function of these cross-reactive T cells
required a larger number of cells than could be isolated ex vivo. We varied the
stimulation protocol to optimize the growth of cross-reactive T cells. We tried the
following three techniques: 1) culture T cells with M1 peptide during week 1 , BMLFI
peptide during week 2 , and M1 peptide during week 3 , 2) culture T cells with BMLF1
peptide during week 1 , M1 peptide during week 2, and BMLF1 peptide during week 3,
culture T cells with M1 and BMLF1 peptides simultaneously for all 3 weeks. Based on
this preliminary experiment, we determined that the growth of cross-reactive T cells was
optimal following the simultaneous stimulation with a 1: 1 ratio of BMLF 1- and M 1-
pulsed T2 cells (Figure 14A). The frequency of cells that co-stained with both BMLF1-
Table 4. CDS T cell Unes from multiple healthy donors responding to 
and BMLF1 stimulation
(IV) M1-stimulated T cell lines: 
Donor PMA+Ionom cin EBV BMLF1 HIV osinase No tide
002 56. 33.
012 78. 23. 1.1
042 94. 17. 1.2 0.4
035 45. 11.9 0.5
044 70.2 2.4 1.9
045 9.2 1.3 1.7
046 72.4 38. 0.2
048 16. 0.3
(EBV) BMLF1-stimulated T cell lines: 
Donor PMA+Ionom cin M 1 EBV BMLFI HIV osinase No tide
002 76. 1.0 59.
O 12 76. 0.4 35.
042 70.4 63.
035 18. 20.
044 93. 67.
045
*** *** *** *** *** ***
046 81.1 38.
048 27. 0.4 14. 0.5 0.4
Control T ceUlines grown with unpulsed T2 cells:
Donor PMA+Ionom cin EBV BMLF1 HIV osinase No tide
002 50.
012 94.
042 95. 0.2 0.3 0.3
035 23. 1.6 0.2 0.2
044 64. 1.9
045 29. 0.2
046 78.
048
* T cell lines were grown for a minimum of 3 weeks and the numbers indicate the % of
CD8 T cells that produced IFNy in response to the respective stimuli. ** not determined
*** no cell line available Bold: % responding to an unelated peptide is greater than 
responding to negative control stimuli and the response of the negative control cell line
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and M1-loaded tetrame:rs increased to a range of 0. 1.1%, in the absence of any co-
staining with a non-specific tetramer (Figure 14B and data not shown). The cross-
reactive cells that bound both tetramers were also able to respond functionally to both
epitopes. They produced MIP- l p, IFNy and TNFa specifically following either M1 or
BMLF1 stimulation, but BMLF1 stimulation appeared to result in a more robust
production of all three cytokines (Figure 15A). However, a peptide titration assay
revealed that these M1 + BMLF1 + cross-reactive T cells actually had a slightly higher
avidity for the Ml epitope (Figure 16A). concentration of lO- M Ml peptide
compared to a 10- M concentration ofBMLFl peptide, resulted in half of the maximum
amount of IFNy produced by this cross-reactive subset. The more robust functional
response to BMLF1 initially observed using a 5 M concentration of peptide appeared to
be an effect of significant TCR downregulation, which decreased the sensitivity of M1
tetramer binding.
The tetramer-based frequency of cross-reactive cells within this T cell line was
lower than the frequency based on function. The subset of cells only able to bind the M 
loaded tetramer produced MIP- 1 p and IFNy, but very little TNFa, in response to BMLF1
stimulation (Figure 15B). The cells that bound only BMLF1-loaded tetramer also
showed some degree of functional cross-reactivity. At least 35% of the BMLF1 + cells
produced a low level of MIP- in response to M1 stimulation, although this cross-
reactive stimulation was not as effcient at inducing IFNy or TNFa production (Figure
15C). A separate peptide titration experiment on this single BMLFI tetramer-positive
subset revealed that the cross-reactive cells present in this sub-population had a similar
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avidity for the M1 and J3MLF1 epitopes , where half the maximum amount of IFNy was
produced near a concentration of 5xl0- M of either peptide (Figure 16B). The avidity
remained high enough to stably bind the BMLF1 tetramer, but was insufficient for stable
binding with the M1 tetramer. Overall, it would appear that the avidity of a cross-
reactive T cell interaction with its alternative ligand is highly variable and that cross-
reactive T cell populations are indeed heterogeneous. Hence, multiple techniques are
required to detect T cell cross-reactivity, including tetramer staining and different
functional assays. As shown here, TCR avidity is an important factor to consider when
detecting cross-reactive T cell responses. An interaction between a cross-reactive T cell
and its alternative ligand may be too weak to stably bind tetramer, but may stil be
sufficient to induce a distinct hierarchy of cytokine production. This is analogous to the
observations that certain non-crossreactive influenza M1-specific clones were unable to
bind M1-loaded tetramers but produced IFNy following M1 peptide stimulation (Lawson
et al. , 2001).
We next sought to clone these cross-reactive cells from a polyclonal T cell line
using the experimental design outlined in Figure 17 A. Briefly, we sorted a cell line with
a relatively high population of cross-reactive cells and allocated single cells that co-
stained with both BMLF1- and M1-loaded tetramers into micro-wells. The single cells
were propagated for two weeks (referred to as clones from here on) and then assessed for
functional specificity. As expected from the T cell line data, there was tremendous
variability in the functional characteristics of each clone in response to either antigen. 
all the clones that grew, 8% produced IFNy following stimulation with either M1 or
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BMLF1 (Figure 17B). ,Similarly, 11% of the different clones analyzed kiled both M1-
and BMLF1-pulsed target cells in a SI chromium release cytotoxicity assay (Figure 17C).
The number of functionally cross-reactive clones varied with the technique used for their
detection and reflected a similar ratio of BMLF1-responders. to Ml-responders (4:1) as
seen in the assessment of IFNy production by the double-tetramer positive population
within a polyclonal T cell line (1.5:1) (Figure 15A). These results definitively show that
individual T cell clones can recognize and respond to both BMLF1 and M1 , two epitopes
which share little sequence similarity.
C. Cross-reactive T cells participate in the lymphoproliferation that defines the 
syndrome
Since we were able to detect cross-reactive cells that recognize M1 and BMLF1
in bulk culture and at a clonal level , we next sought to determine if these cross-reactive
cells participate in the overzealous CD8 T cell response that defines EBV -asssociated 1M.
We noticed that, despite the large expansion of EBV-specific cells, the fTequency (as
percentage of CD8 T cells) of Ml-specific cells in patients with 1M (mean 0.20% , range:
02-0.49%) was similar to that of healthy influenza-immune donors (mean 0.26%,
range: 0.09- 79%). The maintenance of a resting-state frequency suggested that at least
a subset of M1-specific cells was proliferating in response to infection, because non-
crossreactive memory cells should be diluted out by the proliferation of virus-specific
cells. In fact, the average number of M1-specific cells (per ml of blood) was a very
significant 4-fold higher in patients with 1M (0.004 x 10 per ml) compared to healthy
donors (0.001 x 10 per ml) (p= 0.02) (Figure 18A). Five out of 8 patients with 1M had a
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higher than average number of M1-specific cells at presentation, and this number
decreased over the course of the infection with contraction kinetics similar to the BMLFI
response and the overalllymphoproliferation (Figure 18B-D).
These observations suggested that acute EBV infection can activate influenza-
specific memory cells through a TCR-dependent mechanism. The expansion of Ml-
specific memory cells was evident in only 5 of the 8 1M patients examined despite the
fact that all had memory to Ml , and all would have been influenced by any cytokine-
mediated, or bystander, activation. When possible, we also looked for the expansion of a
second memory T cell population, specific for CMV -pp65. Only two 1M patients proved
to be CMV seropositive: El155 and a recent enrollee, E1238. The frequency of pp65-
specific T cells in patients El155 and E1238 dropped during the massive, EBV-induced
lymphoproliferation. At day 0, E1155 and E1238 had a pp65-specific T cell frequency of
0.2% and 0.7% respectively while, by 41-50 days post-presentation, those frequencies
climbed to 0.6% and 1.1 % respectively. These data would suggest that the pp65-specific
memory populations of these two patients did not contain -T cell clones cross-reactive
with EBV and were , therefore, initially diluted out by the extensive proliferation of EBV 
specific T cells.
In an attempt to determine the cross-reactive specificity of the augmented M1-
specific T cell populations , we co-stained freshly isolated CD8 T cells from 1M patients
with M1- and BMLF1-loaded tetramers. Double-positive cross-reactive cells were
prominent in two patients, EllOl and E1l78 (Figure 19). The percentage , as well as the
total number, of cross-reactive cells shifted with this active infection, including a
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considerable increase at day 22 (0.003 x 10 Ml + BMLF1 + cells per m1 of blood) post-
presentation of patient E1101' s clinical symptoms (Figure 19A). This translated to as
many as 1/3 of the T cells specific to the immunodominant BMLF1 epitope being cross-
reactive with MI. Fewer tetramer-defined cross-reactive T cells were detected during
patient El178' s infection, out there was a discemab1e increase in frequency at days 12
and 34 (0.0002 x 10 M1 + BMLF1 + cells per ml of blood) post-presentation with 1M
(Figure 19B). Both of these patients presented with symptoms of 1M but with differences
in regards to the severity. Patient EI10l , who had the higher frequency of Ml +
BMLF1 + cross-reactive cells, presented with severe (grade 5 on a scale of 1-5) symptoms
and clinical signs of 1M, including fatigue sore throat, nausea, myalgia
lymphadenopathy, pharyngitis, and stomatitis (Table SA). Notably, reversion of the
CD4:CD8 T cell ratio was not evident until day 34 post-presentation (Table 5B). 
contrast, patient E 1178 , who had a lower frequency of cross-reactive cells, presented with
only moderate (grade 2-3) symptoms and clinical signs of 1M, including fatigue, loss of
appetite, and only mild hepato-splenomegaly (Table SA). For this patient, CD4:CD8
reversion was observed on days 0 and 6, with a noticeable decrease in ratio again at day
27 post-presentation (Table 5B). The slight increase in CD8 T cell frequency at day 27
was synonymous with a slight increase in viral load, which may have been enough to
alter the hierarchy of responding T cell clones and result in the proliferation of cross-
reactive T cells detected later during the immune response (Figure 20). More patients
will need to be studied to determine whether the correlation between cross-reactivity with
M1 and disease severity will hold, but here we document high levels of cross-reactive T
Table 5. Severity of, 1M in patients having a cross-reactive T cell response
specific for M1 and BMLF1.
Patient E 11 01 Patient E1178:
Symptoms Present Duration Severitv Present Duration Severity
Malaise
Sweats
Sore throat
Loss of
appetite
Nausea
Headache
Chills occas.
Myalgia
Signs Present Duration Severity Present Duration Severity
Adenopathy
Fever
Pharyngitis
Periorbital
edema
Hepatomeqaly
Splenomegaly
Stomatitis
* Duration in days , ** Grade of severity from 1 (mild) to 5 (severe)
Patient E11 01: Patient E1178:
Day
***
CD4:CD8 Day
***
CD4:CD8
165
349
1.4
174
*** Days post-presentation with 1M symptoms
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cells associated with severe 1M pathology.
D. Skewing ofthe Ml-specific VP17+ TCR repertoire duringIM
The M1-specific memory TCR repertoire is organized in a conserved pattern, as
unique TCR clonotypes using the Vp 17 gene family can be ordered in a distinct hierarchy
based on their Jp usage, where Jp2.7 dominates (used by 55-62% of clonotypes),
followed by J 3 (used by 10-20% ofclonotypes) and then often Jp2. , Jp2. , Jp1.1 , or
Jp1.2 at lower, more variable, frequencies (Figure 21A) (Naumov et al. , 2005). 
investigated whether the M I-specific repertoires of Ell Oland Ell 78 were skewed from
this pattern and thereby reflective of cross-reactive TCR-mediated expansions. Due to
limited blood samples , we were unable to sort and sequence the TCRs of the M1-specific
cells directly ex vivo but, instead, generated M1-specific T cell lines from these 
patients. Vp analyses indicated that the M1-specific repertoires of patients EllOl and
El178 were focused on the Vp 17 family, similar to that previously described for healthy
individuals (data not shown) (Lawson et al. , 2001; Lehner et al. , 1995; Moss et al. , 1991;
Naumov et al. , 2003). However, when we sequenced the Vp 17+ clonotypes within the
cell lines derived fTOm both patients, they did not follow the highly conserved
organizational pattern observed in healthy IV -immune donors. At day 22 .post-
presentation, the time point when the number of cross-reactive T cells was highest ex
vivo, the Jp2.3 family was over-represented (30%) while the normally dominant Jp2.
family was vastly under-represented (10%) within the Ml + Vp 17+ repertoire of patient
E1101 (Figure 21B). The skewing of the repertoire was even more pronounced at day
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Table 6. Vp17+ TCR repertoire of the M1-specific T cell lines derived from
1M patients
A. 1M paen: E1101
M1 line 1Q Er,m AA se aR\ 100: l'eode sel. cllM VINDNJ ilntion:
Da22 7 AA H2.1 1 1.2 ASSlCJVGY.1F gcoghtlgglctdalgola:c
H2.2 1 1.2 ASGVGY-TF go;; cmcdagga:lc1-3 1 1.2 .ASTGVGY-TF gcagaxglclagga:a:tlc
1-.3 1 1.2 A&YGY.l' gcagall;c:algg
8AA H4.10 7 1.3 ASRS-YF gcedallc alat
H26 4 2.1.AFF gc gcdtc
1-.24 2. 23 ASSOTQ-YF gcvm"'"V
1-10 2. 23 Q-YF acaltt
H2.4 1 1.6 ASGYNSf'..-F gocglScmalaaa:cc1
H2.5 1 2. 1 ASmG gcEVaSlggalgact
H2.? 1 2.1 ASEQ gclJlgcag ltctc
H2.8 1 2.3 ASRSTDTQ-YF agat ocattU
1-.19 1 2.3 ASRSTDTQ.YF gccQaiaaa:atl
H29 1 2.3 ,tTUQ-YF gc"V"WR" ""acagallt
HZ11 1 2.5 ASa-YF gcQ""'V a:c
H212 1 2.7 ASRiQ.YV gcegatct
1-13 1 27 ASYTQ.YF gcagglgcBl
9AA H214 1 2.6 ASSP-TF gacQ a:gcc
1-15 1 2.3 SSTQ-YF ta:ag aQEaEt
11 AA 1-16 2.1 SlVM at a. cxla: tlcIc
Da165 7M 1-.1 6 1- ASOSYG'(-TF goagaiCWalcgt
14.3 5 1.2 ASYGY-TF gaagaggtla:elggs:c
H4.2 1 1.2 ASOSr-Y-TF gcadalcgBlcgaaacc
H4A 1 1.2 ASYGY.1F DXeQallUttccal '1actc
1-.5 1 1.2 ASG..1F gcagatamcagga:ttc6 1 1.2 AS(JI-Y-Tf gceg
H47 1 1.2 AS(JY-lF QCfQ QQsctlc
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165 (J 3=37%, Jp2.7=3%), again a time when cross-reactive cells could easily be
detected ex vivo (Figure 21B). When the M1-specific population was presumably more
stable at 1 year post-presentation, its repertoire was stil skewed from that typical of a
resting memory state but appeared to be slowly reverting, as the number of clonotypes
using J 2.3 (25%) declined and those using Jp2.7 (14%) were better represented (Figure
21B). Similarly, the M1-specific repertoire of patient E1178 was skewed during the
acute phase of the immune response to EBV , but in a way that was unique from patient
EI101. In the case of patient E 1178 , we found that the Jp 1.2 family was over-
represented within the M1+ VP17+ repertoire (50% at days 19 and 174), ilustrating the
point that a cross-reactive TCR repertoire may be unique to each individual and therefore
not easily predicted (Figure 21 C). This perturbation in the (IV)M1-specific TCR
repertoire of both patients with infectious mononucleosis is highly consistent with the
concept that the cross-reactive M1-specific T cells are expanded in the host in an antigen-
driven maner by EBV-derived epitopes , such as BMLF1. While we did not have access
to their blood prior to EBV infection, the M1 + Vp 17+ repertoires of both 1M patients
were markedly skewed from the conserved organizational pattern of M1 + Vp 17+
repertoires of healthy individuals with long-term immunity to both EBV and IV.
E. Chapter IV summary
We show here that cross-reactive T cells specific to a previously encountered
virus, such as IV, could be major contributors to the overzealous CD8 T cell response
that defines infectious mononucleosis. In 5 out of 8 patients, (IV)M1-specific CD8 T
cells participated in the EBV -induced lymphoproliferation. Two of these 5 patients had
dramatically skewed M1-specific TCR repertoires and increased levels of clearly
identifiable , tetramer-defined, cross-reactive CD8 T cells capable of recognizing the two
dissimilar epitopes (IV)M1 and (EBV)BMLF1. Based on our ability to culture these
cross-reactive cells from 3 out of 8 healthy donors with previous exposure to both
viruses, these cross-reactive cells are maintained in memory and their functional
responses to either antigen can include cytotoxicity and the production of MIP- 1 P, IFNy
and TNFa. Cross-reactive T cells may playa major role in the development of 1M, and
the diversity of their functions may contribute to the severity of the syndrome. These
studies examined only one cross-reactive population, while it is likely that infection with
EBV, a virus with the potential to encode hundreds of epitopes , could reactivate many
memory T cell populations yet undefined. As demonstrated here, the identification of
cross-reactive T cells can be complicated by their ability to recognize alternative peptides
having little sequence similarity to the native peptide, their strict growth requirements in
vitro , and the sensitivity of the different techniques used to detect them. These are all
challenges for future elucidations of individual cross-reactive T cell responses and their
potential impact on the outcome of infectious mononucleosis.
CHAPTER V:
THE CLONAL COMPOSITION OF THE CROSS-REACTIVE CD8 T CELL
RESPONSE WITH SPECIFICITY FOR EBV-BMLFh8o-288 AND IV- 66:
FEATURES OF A CROSS-REACTIVE TCR REPERTOIRE
Our data showed that the cross-reactive T cell population with specificity for M1
and BMLF1 was functionally diverse, some cells producing multiple cytokines (MIP- 1p,
IFNy, TNFa) and some cells producing only one or two cytokines (MIP- 1p, or MIP-
and IFNy) to the same peptide stimulation. Furthermore, functional data also
demonstrated a difference in the avidity between these cross-reactive T cells and each
epitope that was dependent on the peptide used to culture the cells. It remained to be
determined whether these observations could be explained by TCR structural diversity.
Analyses of cross-reactive TCR structure and repertoire organization are an integral part
of our research. The private specificity of each individual' s antigen-specific TCR
repertoire may promote the individual variability in disease severity associated with viral
infections, such as EBV. It is possible that certain TCR structures correlate with
enhanced immunopathology due to the signals they transmit upon cross-reactive
stimulation. A strong signal may exacerbate an inflammatory response and lead to tissue
damage, while a weak signal may result in an altered cytokine profie that could prevent
effcient viral clearance and prolong a damaging inflammatory response. Once cross-
reactive TCR structures are defined, the information can be used to track cross-reactive
clones during the course of infection and between individuals. Cross-reactive TCR
repertoire analyses wil reveal the breadth and, therefore, the likelihood of a cross-
reactive T cell response.. If multiple TCR structures can engage both epitopes , then there
is an increased likelihood that a cross-reactive clone wil be activated and function in
response to infection. This is in contrast to the possible existence of a select few
promiscuous clones, which may be relatively infrequent among individuals.
The Vp 17 family 'is a public component of an M1-specific TCR because of its
pairing with multiple Va families (Naumov et al. , manuscript in preparation) and its
dominance of the M1-specific repertoires of multiple individuals (Lawson et al. , 2001;
Lehner et al. , 1995; Moss et al. , 1991; Naumov et al. , 2005; Naumov et al. , 2003). Based
on the crystal structure, we know that the CDR3p loop, and particularly its arginine98 and
serine99 residues , is paramount in engaging the M1 epitope (Stewart-Jones et al. , 2003).
Less is known about the TCR requirements for interaction with the BMLFI epitope, but
it is interesting that, similar to Vp 17 , the Va 15 family is a public component of a
BMLF1-specific TCR because of its pairing with multiple Vp families and its inclusion
in the BMLF1-specific repertoires of multiple individuals (Anels et al. , 2000; Cohen et
al. , 2002; Lim et aI. , 2000). The experiments presented here were aimed to determine the
structure of this cross-reactive TCR and compare it to the known requirements for
interaction with M1 and BMLFl. Population analyses provided a larger scope on the
potential frequency of cross-reactive TCR structures within an individual's antigen-
specific T cell population.
A. Experimental design
Defining cross-reactive and non-cross reactive T cell populations
Cross-reactive T cells have been identified by their ability to co-stain with M1-
and BMLFl-loaded tetrqmers, and this double-tetramer positive population was shown to
produce MIP- 1p, IFNy, and TNFa following stimulation with either epitope (Chaper IV).
However, subsets of functionally cross-reactive T cells also existed that only effciently
stained with one tetramer type. For instance, a subset (2%) of a CD8 T cell line grown in
the presence of only Ml peptide was more effcient at staining with BMLFl-loaded
tetramer, and we demonstrated that this BMLF1 + subset produced IFNy (29%) in
response to M1 peptide stimulation (Figure 22A). When present, we characterized the
TCR repertoire of both cross-reactive T cells subsets, namely the M1/BMLF1 double-
tetramer positive and the BMLF1 single-tetramer positive populations within M1-specific
T cell lines. We defined non-crossreactive T cells as those cells which only stained with
the tetramer loaded with the peptide used for culturing the cells, namely the M1 single-
tetramer positive population within M1-specific T cell lines and the BMLFI single-
tetramer positive population within BMLF1-specific T cell lines. We either gated on
these distinct, tetramer-defined, T cell subsets to assess TCR usage with Vp-specific
monoclonal antibodies or we sorted these distinct T cell subsets (Figure 22B , C) and used
Vp- and Va-specific primers to assess TCR usage with a PCR-based technology, termed
CDR3 spectratyping.
ii. The TCR repertoire of cultured T cell lines accurately reflects the antigen-
specific TCR repertoire ex vivo
In order to fully investigate the organization and structural diversity of cross-
reactive TCR repertoires, we first ensured that our culturing conditions supported the
growth of all antigen-specific T cell clones. Since the population of BMLF I-specific
-
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memory CD8 T cells in healthy donor D-002 was large enough to sort ex vivo, we
compared the TCR Vp usage of freshly isolated BMLF1-tetramer positive cells with
those grown in the presence ofBMLFl peptide for 4 weeks and found the two repertoires
were almost identical (Figure 23). Usage of the predominant Vp14 (range: 35-63% of
BMLF1 + cells) and Vp16 (range: 18-27% of BMLFI + cells) families was conserved.
Our culturing conditions also effectively supported the growth of low frequency V
families, including Vp17 (2-3%), Vp18 (2-3%), and Vp22 (5-6%). Furthermore, when
we sub-cloned and sequenced their TCR CDR3p region, BMLFI + sub-clones using both
high and low frequency V families were present in both ex vivo and in vitro TCR
repertoires (Figure 23). TCRa-chain usage could not be assessed simultaneously and
therefore, we identified any sub-clone having a unique nucleotide sequence as a unique
Vp clonotype. The same dominant Vp clonotype within each of the Vp 14 , 17 , 18 , and 22
families was present ex vivo and in vitro. The dominant VP16+ c1onotype ex vivo (il:
B 16.2) became co-dominant in vitro with another Vp 16+ - clonotype (ID: B 16. 1) that
differed by only 1 of 8 aa residues comprising the CDR3p loop. These results suggested
that the TCR repertoire of cultured T cell lines accurately reflects the antigen-specific
repertoire present in peripheral blood.
These data were also in agreement with previous reports on BMLF1-specific TCR
structure and BMLF1-specific TCR repertoire organization (Anels et al. , 2000; Callan et
al. , 2000; Cohen et al. , 2002; Lim et al. , 2000). All four of the common Vp families
(VP2 , 16 22) were represented in the BMLF1-specific TCR repertoire of healthy
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Table 7.
100
Full sequences of the CDR3 regions of V and Va clonotypes.
aa sequence CDR3p loop Length taa) Nucleotide sequence of V/NJD/N/J region
AS.GRTNTEA- gccagggtcgacgaiIaclg BlJcttcttl
AS-SQSPGGTQ. gcc;agegccag Ellccmg99999 ac2llactt
AS-SQSPGGTQ- gcCagCagCCBBagCCaggggggacagla:IIC
AS-5QSPGATQ- gccagcagccae.agtcggagcg acaglacttc
AS-SQSPGGTQ- gccagCOIcaglccggc;ggaclllactlc
AS.sOTPGGTQ. gccagcagccag acc;c9999998Cccagt acne
AS-SQSPGGTQ- gccegagccaattctggggggacagtacttc
AS-SOSPGGLE- gccagcagccaatclccggggggcclcgag Cltic
AS-SQSPGGOQ- gcagcagccaatcccc.gggglcagcagllcttc
AS-SQSPGGla. gccagcagccaatcgccccgggattcagtacttc
oAS-SIQGTA YE-Q. gccaglagl8lag aeggg acagcclecgagcagtllllc
AS-SIDRGLINEQ- gccaglaglalaglltag aggSIlli!aalgagagltl!c
AS-SPPAESYEQ. QCagclc lIa:ggCCgagagCt5Cg agcagla:1t
AS-SOGKtAPGEl. gCCBgt:ayga:gglluactllc;gggagclgtmtt
AS-SDGEllPNEQ- getagaglgacg9!g Illctecaatg IIclItttt
AS-SEGQVAPGEL. gcagagtguggIGaggtggcgggagclgmtt
AS-SAGEVFPGEL. gcagcagtgcaggggaattcgggegctgttm
AS-SCGRVAPGEL. gccegcag!gacgcagggliilccgggagclgttl1t
aa sequence CDR3P lOop Length (aa) Nucleotide sequence of V/NJD/N/J region
AS.ORTNTEA. QCagcgglcggacaiIlCtgllllcmcttt
AS-S QSPG GOQ- QClIcagccai!ccccggggglcagagUctl
AS-S OSPG GTO- gccagagagagtccaggggggsccagtec"c
AS-S aSPG OLE. gccagceg lIattcgggggcclcgagacctl
AS.StDGTAYEQ. gcagtagl.agacgggCEagccliIg&gagtacttc
AS-SIMGGNYEQ. gcc""lagt aalggggggcIlIlIIlBtgagagtltl
AS-SIDGTAYEQ. QCagtaglltcgecgggacagcctacagcagt actt
AS-SIDGTAYEQ- gcclIlagtllaglltgggaclllacageglactl
AS-SIDGTAYEQ- gccagtaglllagacggg!lgQ(tllagagtiEtlc
AS-SVDGTAYEQ. gcaglagtgtagacgggacagccla:gagagls:11c
AS-StOOAAYEQ- gcagfagl8lagqgggcagtacagaglacllc
AS-SINGTAYEQ- gcaglaglsllllac99acagtac9agagtactU
AS-SQSDSGYEQ. gccagtegtcagtcaclclggliSElEatllt8ltl
AS-SSGTARYEQ- gcagtagttggllaggctllggla:actt
AS-S1SGTGYEQ- QCagtaglattccgggllagggcctllg agagtlltt
AS-SIPRTGTA YEQ- gcaglagtattclcggacaggg ac.atacagc agtsctfc
AS-SPPAESYEQ. gcl!lclEacagagclacagagtactfc
AS-SDGKLAPGEL- gcagcagcgacggallBatagccGG9 aglglttt
AS-SEGQVAPGEL. gcclI8Qlgllaggtcaglggcggagtgmtt
AS-NEGAGFNYGY. gccBgaagsaggggg!ltfaallltggclacscctfc
AS-SDGEllPNEQ. gccagaglgacgtga8:lcllEclltgagcagtf llC
Length (aa) Nucleotide sequence ofVlNJDlN/J region
gccaggtcgacllaclllgaegclttt
gcagagl1gglcggnaclBClilitgagagtttf
gccagagaggtaclllQQegtt!llItgagagttclt
gcagcgglcggqllaclltfgaagttltt
gcagllmcgggaclagtctllaatgagagllclt
Figure 23:
A Donor D-002 ex vivo BMLF1 + sequences.Jp Clonotype ID Frequency14 11 814.
Total un(qua t;onolyp: 
Tolal8Dquam:es analyzed: 
816.
816.86 
816. 5 
816-
816.
816.
816.
816,
816. 1 .-
To/al un/quo ckmorype: 9
Tola/sequences analyzed' 
817.
817. 2 
Tolitfuniquo clonotyps: 2
Totat sequences analyzed: 
818.
Total unique clonDlypes: 1
Total sequances analyed. 8221 
822.04 
822.
822.
822.
ToIafuniquacloncJtys. 5
Tolal SBquenc65 analyzed: 
B. Donor D-002 in vitro BMLF1 + sequences.ovp Jp . ClonotypelD Frequency14 1.1 814.
ToIaluniqueclonotyp6S: 1
Totat sequencos analyzed: 
816_
816.
816.
Tola/uniquecionotys: 3
Toleisequences analyzed: 
817-
817.
817.
817.817.4 
917.
817.
817.
817. 0 81711 
817, 2 
817.
T0I81 unique clonoty. 
Tolal sequenct1 analyzed: 105
818.
Tolaiuniqwclonotys: 
ToIalsBquonceS enalyzed: 
822.
822.
822.
B22.
Tola/ unique clonofys: "
ToIa/sBqUIncB. l!nalyzed: 20
Figure 27:
A. Donor D-002 cross-reactive sequences in an M1-specific T cell line.Jp Clonotype ID Frequency aa sequence CDR3p loop
14 11 814. 16 AS-GRTNTEA-1 14. 4 AS-SSGSSGYVNEQ.1 14.15 1 AS-SLGTSGSYNEQ.1 104.24 1 AS-GRTNIEA.1 14- 8 1 AS-SFGTSPYNEO.
ToIalunIqUIclono/y: 5
ToIa/sBquencesanafyzed: 23
11.
17.27 
11. 3 1716 
17.26 1721 
11.
17. 2 
17.20 
17.
17.28 
17.32 
17. 6 
17.39 
17.4  
17.57 
17.62 
17.
11.30 
17. 7 
17.38 
17.43 
17.54 
17.6  
17. 1 
17. 9 
17.56 1740 
AS-SrRSSYEQ-
AS-SIDGTAYEQ.
AS-SIRSSYEQ-
AS-SVRSSYEO-
AS-5TRSSYEQ-
AS-SMRSAYEQ-
AS-SJRSSYEQ-
AS-5 IRSS YEo-YF
AS-5IRSSYEQ.
AS-5IRSSYEQ.
AS-5IRSSYEQ.
AS-SIRSSYEQ.
AS-SIRSSYEQ.
AS-SIRSSYEQ-
AS-5IRSSYEQ.
AS-SIRSSYEQ.
AS-SIRSSYEYF
AS-SVRSSYEQYF
AS-SVRSSYEQ. 
AS-SVRSSVEQ.
AS-VRSSYEQ-
AS-SVRSSYEQ-
AS-STRSSYEQ.
AS-SLRSSYEQ.
AS-5MRSSYEQ-
AS-SSRSSYEQ.
AS-SSRSAYEQ-
AS-SMRAYEQ.
gceglagtllllagglllctqllagtlEllc
. gccegtagtalagqgglllItacgBQaglacttc
gccegtaglllacgtctcltqBglIlactk
gcaglagtgllagaaglclacgaglIta:tl
gcaglagtiEcg aalclacagcagtactfcQClllagl!lgcgaglqllaglllllc
gcagtagtalacgaalclac agagta:tI
gcagiaglilllagctctacagagtactfc
gccagtlllattclltagttacagagtactl
gcclllsglailiagglcttlacQagcaglactt
gcaglaglS1aggaglttac agagtactl
gccaglagllltctltcllllIcagtaclt
gcaglaglataQllaglclacgagcagtactl
gcagtsgllllclclltecegaglacll
gcsglagtllactagtclacgagllllEtlc
gcaglagtlleggagltllEg8Q1911C1I
gcaglagtEaggltlcl8ClIagllltI
gcagtagtglClIuglctllagagtacll
gcagtaglglcagg8QtclacagagllltI
gclltaglglqgaglcllE8gagl.,ttc
gcagagtgttegtctcUqagagtactf
gcagtagtgtqtlltclacgag-.tllltc
gcCagtagtll1I9ttttclqagagilEttc
gcl!lagligagaagtclacgagagIIlUC
gcClltagtllgaggaglclqagllllll1c
gcaglaglagtcgaglclacagagtiilt
gcClltsglttclltcCClacagagl8:tf
gccagtaglllgcggc89tlllI agl actl
(Table 7 continued)
17.
17.
17.
17.
17.
17-
17.
17.
17.
17.
17,
17.
17.48
17.
Total unique r:onotypes:
Tota/sequences analyzed:
AS-SKRSTDTQ-
AS-SQRSTDTQ-
AS-SPRSTDTQ-
AS.SPRSTDTQ-
AG.SGRSTDTO-
AS.SGRSTDTQ-
AS-STRSSDTQ-
AS-SIRSADTQ-'yF
AS-SIRPADTO-
AS.SALAGPTYNEQ-
AS-SIGTGEQ.
AS-$ IETTSGSSYNEQ-
AS-$ IGIYGY.
AS-SSOSYGY-
B. Donor 0-002 non-cross reactive M1+ sequences in an M1-specifc T cell line.vp Jj3 Clonotype ID Frequency aa sequence CDR3p loop17 2.7 43.27 6 AS.SMRSSYEQ.
17.27. 5 AS.SIRSSYEQ.
23.  3 AS.SIRSSYEQ-
28. 7 3 AS-SIRSSYEO. 2 AS-SIRSSYEQ-
25. 1 2 AS-StRSSYEQ-
36. 7 2 AS-STRSSYEQ.
51.2  2 AS.SVRSSYEQ.
72. 7 2 AS.ALRSSYEQ. 
73.  2 AS.SIRAAYEQ-
64.27 2 AS-SIRSGYEO-
86.  2 AS-SFRSAYEO-27 1 AS.SIRSSYEQ- 1 AS-SIRSSYEa-
19.27 1 AS-SIRSSYEO-
22.  1 AS.SIRSSYEO-
29. 7 1 AS-SIRSSYEQ-
35.  1 AS-STRSSYEO-
38.27 1 A5-STRSSYEa.
39.  1 AS.STRSSYER.
40.27 1 AS-STRSSYER-
41.  1 AS.STRSSYER-
49.27 1 AS-SVRSSYEO-
59.  1 AS-SSRSAYEO-27 1 AS.SSRSAYEO-
65.  1 AS-SMRSAYEO-9127 1 AS-SIRSAYEQ-23 3 AS-SGRSTDTO. 1 AS-SPRSGDTQ.
10.23 1 AS-SSRSTDTO.
16.  1 AS-SQRSTDTO-
18.23 1 AS-SaRSTDTO-
19.  1 AS-SORSTDTO- YF
25. 3 1 AS-STRSSDTO-
30.  1 AS-SIRSTDTO-
32. 3 1 AS-STRSADIQ.3323 1 AS.SMRTGDTO.21 1 AT-SGRAGVEO. 1 AS.SYRSSNEQ-21 2 AS-SIGTGEQ-
Total unique c/onotypes: 
Tolal saquences analyzed: 
Length (a a)
Figure 28:
A. Donor 0-002 non-cross reactive BMLF1+ sequences in an BMLF1-specific T cell line.Va Ja Cfonotype ID Frequency aa .equenc. CDR3a loop ULength (Ia)15 45 81 38 AE-RKGGADGL-TF B2 5 AE-YSSASKI-  37 3 2 AE.STGKL-IF 41 B47 2 AE-SKGAL-NF 15 816 1 AE-SEGTAP-I  831 1 AE-YSSAPKI. F 838 1 AE-SRGAL-T  
Total unfque cfonotypes: 
Tota/ sequences analyzed: 
B. Donor 0-002 cross reactive sequences in an M1-specific T cell line.Va Ja Clonotype ID Frequency aa .equenn CDR3a loop15 45 81 35 AE-RKGGADGL.31 X5 5 AE-STOKL.13 3 3 AE- lGYQKV-5 X12 3 AE-SEGTAL.11 45 2 AE-DRD5TL.5 816 1 AE-5EGTAP.4  X23 1 AE-RKGGANGL-
Total unique cfonotypes: 
Tolal sequences analyzed: 
C. Donor D-002 non-crossreactive M1+ sequences in an M1-specific T cell line.Va Ja Clonotype ID Frequency aa .equenc. CDR3a loop15 23 M2 19 AE-ONOOGKL-1 6 AE-SPSLNTGFQKL-43 Me 3 AE-SNNDM-2 70 2 AE-PGSaGNl-4  M25 1 AE-PGSQGNl-VF
Total unique c/onotypes: 
Tala/sequences analyzed: 
Length (n)
Length (Ia)
101
gccaglagcaaaagg agcacagalacgcaglatl II
gccaglaglcagaga agcacag alacgcag lalm
gccagleglccccggagcacag atacgcaglalill
gccaglagtccccggtccacag atacgcaglalHl
gccg 9 lagcg 9 acgg egcacagalacgcag talill
gccaglagcgggag aagcacagalacgcagl altll
gccaglagleccegalcglcag alacgcaglaillt
gccaglaglalaaggloggcgg alacgcaglaliU
gceag taglataaggccggcgg atacgc aglalll
gcoagUccgcgclagcgggaccaacctacaalg agcag Ucllc
gccaglag lalcgglacaggggegcag tlcltc
gcceglagle leg ag acgaelagcgg aagctcclaca algagca.gltcllc
gccegiaglalcgggeiclalggclaeaccltcggllcg
gccaglagllegggcagllaig gclaceccllcgg tlcg
Nucleotide .equence of V/N/D/N/J region
gcceg taglatgegg aglleclacg IIg clg lacllc
gCCligleg talaag aagclcclacgagcaglecltc
gccaglag !alccgtlcglcclacg agcaglaeltc
gccaglagtalcaggagclcclacg agcaglacltc
gccaglaglalccg aagclcclaeg agcaglactlc
gccag taglalacg tagclcclacg agcagtactlc
gccaglagtaccagg agclcctBcg agcaglacllc
gccaglaglg Icagaagclcctacgagcagtllcltc
gccaglaglilgagaagclcclacg agcagl8cltc
gccagl aglaccggcagcclacgagcaglacilc
gccagiagiallcgaleaggglacgagcag laclte
gccagtagctllaggaglgcclacgagcaglaellc
gccaglaglaUaggegclcctacg agcaglacltc
gccaglaglalcag ugclcclecg ag caglacllc
geeagll!gtellcggagclcclacgagcaglaclle
geeegiagiallcgtlcglcci acg agc aglacllc
gccagtagtetacggagclcclacg ag caglacllc
gccaglaglacgcg a agclcclacgagcaglacl Ic
gcc8glaglacc agglcllcclacgagcaglaollc
gccagtag leclaggagctcclacgagcaglacllc
gccagtaglecacg aletlcclacgagcagtacltc
gccaglaglaccaggagclcclacgagcaglactlc
gccegteglg IIcggagctcctacg !!gcaglaellc
gcca.g leg Itccagg Iccgcelacg agc8glacltc
gccaglag Ilclcgalccgcclacgagcaglactlc
gccaglaglalgcggegcgcctacg agcaglacllc
gcceglaglalccgcagtgcclacgageag I acllc
gccaglagcggg 8g aagcaceg alacgcaglettl1
gccag tIecccgcgcag Igggg alaccaglaUIt
gccaglag IIce8gatccacag etacgcaglalUt
gccaglag tcagag aagcacagaiacgcaglallil
gccegilcegggagg ageacagataegcaglalll
gccag I agcagag aagc aeagalaegcaglaUIl
geeag I ag lacccgatcglcag elacgcaglalll
gcceglag lalaag aagcacag alacgcag laUlI
gcceglagtaclag a agcgcagalacgcaglatll
gccagtaglalgcgg accgglg atacccagtalill
gccacctccggccgggccgggllgegcaglleUc
gccagtagltacagg tcglcea elgagcagllcllc
gccegiaglatcgglacagggg agcagllcllc
Nucleotide .equen..e ofV/N/D/N/J region
gcag egageaaagg agglgclgacgg aelcacclU
gcag agtacagcaglgcHccaagalaatclU
gcegaglcaacaggceaacla alctl
gceg ag aglauggcgceclcaacUc
gctlg 8gaglg 8aggaaclgclccgalctll
gceg aglac8go agtgelcccllagaleatctl
gcegag 8g tcgagg agcacllaclll
Nucleotide ..quence of V/N/D/N/J region
gClIg IIg agaaaegg agglgclg acgR flelcaccUl
gcag aglcg acaggcaaaciaelcllt
gceg agllgggllaccaguegUaccll1
gcag ag ag Ig aagg 8aclgclelg alcll
gcag I!ggaccggg acagcaccclcaccUI
gClIg ag aglga agg aaclgclccgalcll
gcag ageg aaaeggagglgcleacgg acleaecttl
Nucleot(de ..quen..e ofV/N/D/N/J region
gcegaggalaacoagggaggeaagclialctte
gcag ag egccctlccclgaacecaggclUcageaacllgla III
gellg agl!glaacaalgaoetgcgclll
gceg agccggg aagcc aaggaaalcicalcllt
gcag agccggaag ccaaggeulclcgtcHl
Each unique clonotype is distinguished by Its unique nucleotide sequence. . TCR variable (V) region nomenclature based on Arden et al.
, ..
CDR3 loop length according to Chothia et al. shown flanked by two framework regions.
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donor D-002 (Figure 23). Furthermore, we confirmed the observation that a given Vp
family is often comprised of only 1-2 unique clonotypes (Callan et al. , 2000). For donor
002, as few as 2 clonotypes accounted for greater than 60% of each Vp population
investigated (Figure 23). By comparison, the c1onotypes within each Vp family varied in
their length and the aa sequence of their CDR3p loop, the most common residue among
them being glycine (detected in the c1onotypes of 4 of 5 Vp families). The dominant Vp
clonotypes detected in our study used the conserved Jp family and/or CDR3p motif
associated with those Vp families for which public specificities have previously been
reported (Table 2). VP16+ c1onotypes used the common CDR3p motif AS-SQSPGGTQ-
YF and had less restrictions on their Jp usage, while VP22+ clonotypes were more
restricted by the usage of Jp2. 1 or Jp2.2 than the aa sequence of their CDR3p loop, AS-
S*G*V*PGEL-FF (Figure 23) (Lim et al. , 2000). In addition, these data revealed novel
observations on the BMLF1-specific TCR repertoire, such as the usage of Vp families
, 17 and 18. All three Vp families were comprised of one dominant c1onotype with a
CDR3p loop sequence that may be conserved in other donors with BMLF1-specific
repertoires that include these particular Vp families (Figure 23). Overall, the 5 Vp
families analyzed here (VP14, 16, 17, 18 , 22) represented over 80% of the BMLF1-
specific repertoire of donor D-002, and the total number of unique Vp clonotypes
identified out of the total number of sequences analyzed was as few as 18 out of 201
isolated ex vivo and 21 out of 160 isolated in vitro (Table 7), reaffirming that the
BMLF1-specific TCR repertoire is quite oligoc1onal in comparison to the (IV)M1-
103
specific TCR repertoire, where as many as 141 umque c1onotypes were previously
identified from 501 total sequences analyzed within the Vp 17 family alone (Naumov et
al. , 1998; Naumov et al. , 2003).
B. Characterization of cross-reactive TCR structure and repertoire organization
We used tetramers and Vp-specific monoclonal antibodies to first describe the
cross-reactive TCR repertoires of 2 healthy donors and 4 patients with acute EBV
infection. Among these 6 individuals, we determined that each cross-reactive repertoire
contained 1 or more of 10 different Vp families, including Vpl , 2 , 4 , 5. , 7. , 16 , 17
21.3 and 22 (Figures 24, 25). Thus , a wide range of TCR structures appeared capable of
recognizing the two dissimilar epitopes M1 and BMLF1. We found no discernable
difference in the breadth of the cross-reactive repertoires of healthy donors compared to
patients with acute EBV infection. While we were unable to screen for all of the known
Vp families due to the lack of the appropriate monoclonal antibodies, the cross-reactive
repertoire of at least one individual used as few as 1 Vp family (patient E 1178 , Vp 1) and
the cross-reactive repertoire of another individual used as many as 6 different Vp families
(patient Ell09, Vp4, 5. , 7.2, 14, 17 and 21.3). The breadth of the cross-reactive Vp
repertoire was most extensive ( 5 Vp families) in the two patients, EllOl and Ell09
having two distinct, tetramer-defined, sub-populations of cross-reactive cells (Figures 24
25). The most common Vp family detected among the cross-reactive repertoires of all
individuals was Vp4 , used by 4 out of 6 individuals.
We have just begun to assess the Va usage of these same cross-reactive T cell
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subsets. We isolated tne BMLF1 + cross-reactive T cell subset within the M1-specific
line derived from healthy donor D-002 (Figure 22B) and, in a screen that included
primers specific for 24 different Va families, this cross-reactive repertoire included at
least 9 different Va families (Va1b , 2 , 6 , 10, 11 , 15 23 and 24) (Figure 26A). Thus
as was observed during analyses of Vp usage, a wide range of Va families can
potentially mediate TCR interaction with these two dissimilar epitopes.
C. Distinguishing features of the cross-reactive TCR repertoire
Population analyses of TCR p-chain usage
Given the wide range of possible cross-reactive TCR structures and the individual
variability previously documented for both the Vp composition of BMLF1-specific
repertoires and the clonal composition of Vp 17+ Ml-specific repertoires , we compared
the cross-reactive and non-crossreactive repertoires of each individual separately for
insight on the organization behind each cross-reactive repertoire. Despite representing a
subset of the M1-specific and BMLF1-specific T cell populations, we observed several
aspects of the cross-reactive TCR repertoire that made it unique. For instance, although
the same Vp families were often used by non-cross-reactive and cross-reactive T cell
subsets, the proportions of those Vp families were always altered in the cross-reactive
repertoires. In the case of 1M patient Ell 01 , a cross-reactive population that co-stained
with both M1- and BMLF1-loaded tetramers predominantly used Vp17, as did this
patient's non-cross-reactive M1-specific population , but that particular cross-reactive
repertoire also included low frequency Vp families (VP2 and 4) which were not
components of the non-crossreactive Ml-specific repertoire (Figure 24). In addition, the
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cross-reactive subset that bound only BMLF1-loaded tetramer, within the M1-specific T
cell line derived from this same patient, used three V families common to the non-
crossreactive BMLF I-specific repertoire (VP2 , 4 and 22), but remained distinct by using
an increased frequency of Vp16 (6%) which was barely detectable in the non-
crossreactive BMLF I-speCific repertoire (Figure 24).
In addition to using altered proportions of the same Vp families , selective gating
on cross-reactive T cell subsets appeared to enhance the detection of different Vp
families used more frequently by cross-reactive than non-cross-reactive T cells. The
cross-reactive repertoires of 4 out of 6 individuals investigated included 1 or more Vp
families not detected within either of that individual's non-crossreactive repertoires
(Figure 25A, B). In some cases, the Vp families strictly detected in the cross-reactive
repertoire included Vp families common to other individuals, such as Vp4, 16 and 22. In
other cases, the Vp families strictly detected in the cross-reactive repertoire were rare
even among the repertoires of other individuals, such as V , 7.2 and 21.3. The most
extreme example of this was observed upon the repertoire analysis of patient E1217
whose cross-reactive repertoire consisted entirely of two Vp families (V 1 and Vp21.
that were not detectable in either non-crossreactive repertoire.
There were also differences on a clonal level that made the cross-reactive
repertoire distinct from either non-crossreactive repertoire. When we sub-cloned and
sequenced Vp 14+ T cells derived from healthy donor D-002 , representing the dominant
Vp family of both the cross-reactive and non-crossreactive BMLFl-specific repertoires
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we detected an increase number of Vp 14+ clonotypes in the cross-reactive population (5
unique clonotypes out of 23 total sequences) compared to the restricted clonal
composition of the non-crossreactive Vp 14+ BMLF I-specific population (1 unique
clonotype out of 10 total sequences) (Figures 23 and 27A). Three of the four novel
14+ cross-reactive clonotypes used an alternative Jp family (J 1) and a longer
CDR3 loop (lO- llaa length). Interestingly, we had previously sub-cloned and
sequenced the small VP14+ subset (2%) within the non-crossreactive M1-specific
population and detected only 1 unique clonotype out of 82 total sequences (Jp2. , 9aa
length, AS-SSRGHGNEQ-FF), which had a surprisingly similar structure to the newly
identified cross-reactive VP14+ clonotypes (Jp2. , 10-11aa length, CDR3p motif: AS-
S*GTSG*YNQ-FF) (Figure 27 A) (Naumov et al. , 2005). The longer CDR3p regions
were extended by multiple glycine or serine residues at the point of gene recombination.
Both amino acid residues have uncharged, non-blllky side chains that may give the
CDR3p loop flexibility and potentially allow these TCRs to adapt to an alternative ligand
(Abergel and Claverie, 1991; Bentley and Maruzza, 1996). Similarly, we sub-cloned
and sequenced several novel Vp 17+ cross-reactive clonotypes , the dominant Vp family
of the non-crossreactive M I-specific repertoire. The majority of the cross-reactive
VP17+ repertoire (64% of the unique clonotypes) was comprised of new clonotypes that
were not previously detected in either non-crossreactive repertoire and, once again
included clonotypes with extended CDR3p regions (Figure 27B).
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ii. Population analyses of TCR a-chain usage
Va repertoire analyses of T cell populations derived from healthy donor D-002
were performed using a PCR-based technique and, therefore , did not reveal the relative
frequencies of Va family usage. However, we did compare the clonal composition of
several Va families used by these T cell populations by running the Va-specific CDR3
spectratyping reactions of each population on the same gel (Figure 26C). This technique
revealed differences between the repertoires of these populations in the lengths of the
CDR3a regions, an indication of clonal differences within a given Va family. This was
evident among Va11+ cross-reactive T cells which clearly expressed a longer CDR3a
region than either non-crossreactive Ml-specific or non-crossreactive BMLF1-specific T
cells (Figure 26C). Similarly, the CDR3a spectratyping pattern of Va20+ cross-reactive
T cells also appeared distinct from that of either non-crossreactive population. Unique
TCR a-chain features of the cross-reactive repertoire were also observed at the clonal
level. Despite having some similarities with the BMLFl-specific Va15+ repertoire, the
cross-reactive Va15+ repertoire included clonotypes that expressed unique Ja families
(Ja11 and Ja13) and CDR3a loops 6aa long, a length which was more frequent in the
cross-reactive repertoire (18% of sequences) than the non-crossreactive BMLF I-specific
repertoire (2% of sequences) (Figure 28A, B). Furthermore, there were no similarities
between the cross-reactive and non-crossreactive M1-specific Va15+ repertoires (Figure
28C).
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D. Similar features between the cross-reactive and non-crossreactive TCR
repertoires
Population analyses of TCR p-chain usage
Since the cross-reactive T cell population represents a subset of the M1- and
BMLF1-specific T cell populations, we would expect that the cross-reactive TCR
repertoire would share some features of both antigen-specific repertoires. Analyses of T
cell lines derived from 1M patient EllOl revealed that the Vp repertoires of the cross-
reactive T cell subsets included multiple Vp families that were present in the non-
crossreactive M1- and BMLF1-specific repertoires (Figure 24). The repertoire of the
cross-reactive population which co-stained with M1- and BMLF1-loaded tetramers
resembled that of the non-crossreactive M1-specific population because cells
predominantly used Vp17 ( 80%). In contrast, the repertoire of the cross-reactive
population which grew in response to M1 and bound only BMLF1-loaded tetramer used
Vp2 (12%), Vp4 (18%), Vp16 (6%), and Vp22 (8%) but not Vp17. We did not detect a
dominant Vp family within this cross-reactive population, suggesting that either the
tetramer staining was somehow blocking the dominant Vp-specific antibody staining or
more likely, that approximately 50% of this repertoire is comprised of other. Vp families
which we do not have antibodies to detect. The same was true of the Vp repertoire of the
non-crossreactive BMLFl-specific population, which used Vp2 (13%), Vp4 (19%), and
22 (10%) to account for less than 50% of the population. Overall , the M1-specific
Vp 17 family was predominantly used by the sub-population of cross-reactive cells able to
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effciently bind the M1-loaded tetramer, while the BMLF1-specific Vp families 2 , 4 and
22 were predominantly used by the sub-population of cross-reactive cells better able to
bind the BMLF1- loaded tetramer.
Similar analyses of other individuals included in our study also followed this
trend. As was the case for 1M patient EI101 , the Ml-specific T cell line derived from 
patient E1109 also contained two distinct, tetramer-defined, cross-reactive T cell subsets
and the subset that co-stained with both tetramers predominantly used the Vp 17 family,
which was also known to dominate the non-crossreactive Ml-specific repertoire (Figure
25A, C). Once again, the Vp 17 family was absent from the repertoire of the cross-
reactive subset that bound only BMLFl- loaded tetramer. Taken together, these data
suggested that Vp17 was required for stable binding of the Ml-loaded tetramer, as has
been previously reported (Lawson et al. , 2001), and that cross-reactive TCRs with high
avidity for M1 wi1likely use Vp17. Based on our data, we can then infer that cross-
reactive TCRs with lower avidity for M1 , and therefore not staining with M1-loaded
tetramer, may use non- Vp 17 families that are present in the BMLF I-specific repertoire.
In general , previous studies would suggest that the BMLF1-specific TCR repertoires of
most individuals include at least 1 of 4 common Vp. families (VP2 , 4, 16, 22). Each of
these 4 Vp families was represented at least once among the cross-reactive repertoires of
the 6 individuals investigated (Figure 25A, B).
Similarities between the cross-reactive and non-cross-reactive Vp repertoires
were also evident on a clonal level. We sub-cloned and sequenced the CDR3p regions of
cross-reactive and non-crossreactive T cell subsets derived from healthy donor D-002.
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This donor s non-crossreactive BMLF I-specific population predominantly used Vp 14
(66%), which was used by 57% of the cross-reactive population (Figure 25B, D). The
most frequently detected Vp 14+ clonotype in the cross-reactive population (il: B 14.
Jp1.1 , 7aa length) was the same clonotype that dominated the non-crossreactive BMLF1-
specific repertoire of this donor (Figures 23 and 27 A). On the other hand, this donor
non-crossreactive M I-specific population predominantly used Vp 17 (81 %), which was
used by .:1 % of the cross-reactive population (Figure 25B , C). This small population of
Vp 17+ cross-reactive cells was surprisingly diverse at the clonal level, comprised of 42
unique clonotypes out of 55 total sequences analyzed (Figure 27B). There was no
apparent skewing of the repertoire by one particular clonotype or any alteration of the Jp
hierarchy typical of resting M1 + Vp 17+ memory T cell populations (Naumov et al.
2005; Naumov et al. , 2003). The cross-reactive Vp 17+ clonotypes of donor D-002 could
be arranged in a power law-like distribution based on their frequency of detection, as has
previously been used to describe the polyclonality of the VP17+ M1-specific memory T
cell repertoire (Figure 27B , C) (Naumov et al. , 2005; Naumov et aI. , 2003). In agreement
with the literature, *RS* was the dominant CDR3p motif found within the non-
crossreactive M1 + Vp 17+ repertoire (the predominant IRSS sequence was used by 25%
of the unique clonotypes) and remained dominant with an even higher frequency within
the cross-reactive population (the predominant IRSS sequence was used by 31 % of the
unique cross-reactive c1onotypes), including the most frequently detected clonotype (il:
17.3 , frequency: 7% of total sequences) (Figure 27B , C) (Lehner et al. , 1995; Moss et al.
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1991; Naumov et al. , 1998). Interestingly, this cross-reactive VP17+ repertoire also had
one clonotype in common with the non-crossreactive BMLFl-specific repertoire, which
was the second most frequently detected V 17+ clonotype in the cross-reactive
population (ID: B17. , frequency: 5% of total sequences) and was the dominant VP17+
clonotype within the BMLF1-specific population (frequency: 84% of total sequences)
having a CDR3p region that was 1aa residue longer (9aa length) than the IRSS-
containing regions (Figures 23 and 27B).
ii. Population analyses of TCR a-chain usage
Va repertoire analyses also revealed similarities between cross-reactive and non-
crossreactive T cell subsets derived from healthy donor D-002. Non-crossreactive
BMLF1-specific cells used Va2, 10, 11 , 15 , 22 and 23 , along with some other families
that may have been at the limit of detection using this protocol (Figure 26B). All but
Va22 were also detected in the cross-reactive repertoire (Figure 26A). The Va repertoire
of non-crossreactive Ml-specific cells also included a wide range of Va familes, most
consistently including Va1b , 2 , 10 and 24, but with many additional Va families being
detected such as Va6, 11 , 15 , 20 and 23 (Figure 26C). All of these families were also
detected in the cross-reactive repertoire (Figure 26A). In order to compare the CDR3a
lengths of cross-reactive and non-crossreactive T cells using the same Va family, we ran
the corresponding reactions on the same gel (Figure 26C). This further revealed that the
cross-reactive cells often express similar CDR3a lengths to both non-crossreactive T cell
populations. For example, the cross-reactive ValO spectratyping analysis . closely
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resembled that of the. corresponding analysis on the non-crossreactive M1-specific
population, while the cross-reactive Va2 and Va15 spectratyping analyses more closely
resembled that of the corresponding analyses on the non-crossreactive BMLF1-specific
population. As previously mentioned, Va 15 is a component of the public BMLF1-
specific TCR and is likely important for interaction with the BMLF1 epitope. To verify
the similarity of these repertoires on a clonal level, we sub-cloned and seqllenced the
Va15+ TCRs from all three T cell subsets (Figure 28). We detected the identical
dominant Va15+ clonotype (il: B1) in both the cross-reactive (frequency: 70% of total
sequences) and non-crossreactive BMLF1-specific populations (frequency: 76% of total
sequences) (Figure 28A, B).
ii. TCR structure of cross-reactive T cell clones
In light of so many similarities between the cross-reactive and non-crossreactive
repertoires, we sought to co-sequence the TCR a- and p-chains of cross-reactive T cell
clones in order to determine if it was the pairing of a BMLF1-specific a-chain with an
M1-specific p-chain, or vice versa, that enabled a cross-reactive TCR to engage both
epitopes. In preliminary experiments, we sequenced three cross-reactive T cell clones
that co-stained with both tetramers (Table 8). Two of the clones used a TCR with a- and
p-chains that were both detected in the same epitope-specific repertoire. Clone ID4 used
Va1b/Ja42 (AV-NSGGGSQGNL-IF) and VP17/Jp2.7 (AS-SSRSSYEQ-YF), and both
CDR3 sequences were previously detected within M1-specific T cell populations, but in
experiments that did not exclude potentially cross-reactive cells (Naumov et al. , 2005)
(Naumov et al. , manuscript in preparation). Interestingly, the CDR3 regions of both
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Table 8. TCR structure of cross-reactive T cell clones.
famil famil COR3 uence Va famil Ja famil COR3a se uence
104 AS-SSRSSYEQ- YF A V-NSGGGSQGNL-
4E5 AS-SQSPGGTQ- YF AE- YSSASKI-
1F8 SA-RSGVGNTI- YF AE-DRDSTL- TF
T cell clones were each derived from a single T cell that co-stained with M1- and
BMLF1-loaded tetramers and that was cultured for 2 weeks. The V region
nomenclature is according to (Arden et al. , 1995) and the CDR3 junction region
is shown flanked by two framework regions. Bolded residues are the N-
nucleotides added to the junction region and , in the case of the p-chain , include
the 0 region.
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chains were extended QY non-bulky aa residues, glycine and serine, which may have
enhanced the flexibility of this M1-specific TCR and allowed it to engage the BMLF1
epitope (Abergel and Claverie, 1991; Bentley and Mariuzza, 1996). Clone 4E5 used
Va15/Ja3 (AE-YSSASKI-IF) and VP16/Jp2.5 (AS-SQSPGGTQ-YF), and both CDR3
sequences were previously detected within BMLF1-specific T cell populations (Figures
23 and 28). Once again, serine and glycine residues were prominent in both chains.
Finally, clone 1F8 used Va IS/JaIl (AE-DRDSTL-TF) and VP2/Jp1.3 (SA-
RSGVGNTI-YF), and neither of these CDR3 sequences appears to be a common
component of M1- or BMLF1-specific TCRs. This CDR3a region does not fit the
predicted BMLF1-specific Va15+ public motif (Table 2) and, in our study, was only
detected in the cross-reactive TCR repertoire (Figure 28). While the CDR3 region does
resemble a predicted BMLF1-specific VP2+ public motif (Table 2), the non-germline
encoded serine residue is a rare component. It is possible that T cell clones expressing
this serine residue in their CDR3p region are better apt to interact with the M1 epitope
due to its juxtaposition to the arginine residue, the two most conserved residues of the
*RS* public motif for contacting the M1 peptide according to the crystal structure of
JM22 TCR/1/HLA-A2 (Stewart-Jones et al. , 2003).
E. The cross-reactive TCR repertoire is unique to each individual
Cross-reactive TCR Vp analyses of 6 different individuals revealed the wide
range of Vp families capable of recognizing both M1 and BMLF1 epitopes , but these
analyses also demonstrated the individual variability in the organizational pattern of each
cross-reactive TCR repertoire (Figure 25). It appeared that the specific combination of
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BMLF1-specific Vp families used by each individual influenced the specific combination
of cross-reactive Vp families used by that individual. For example , the non-crossreactive
BMLF1-specific repertoire of donor D-042 included Vp4 and Vp16, but not Vp2 or
Vp22 , and the cross-reactive repertoire of this donor reflected that by including one of
the two Vp families known to be present, Vp4 (Figure 25B , D). Thus , the composition of
the non-crossreactive Vp repertoire clearly influenced the organization of the cross-
reactive Vp repertoire. The individual variability associated with both BMLF1-specific
and, through association, cross-reactive Vp repertoires stems from the private specificity
of each individual's pool of precursor T cells (naIve and memory) capable of activation
by the BMLFI epitope. Thus , there did not appear to be a public V region component of
cross-reactive TCRs , and the individual variability of each cross-reactive repertoire may
contribute to the individual variability in disease severity associated with cross-reactive T
cell responses.
F. Chapter V summary
In this study, we aimed to characterize the structure(s) of this specific cross-
reactive TCR and the organization of the cross-reactive TCR repertoire. The epitope .
sequence of M1 (GILGFVFTL) shares only 3 of 9 aa residues with that of BMLF1
(GLCTLV AML), at least 1 of which is important for MHC binding (Engelhard, 1994).
Hence, this is not an obvious case of molecular mimicry, and it is likely that the TCR
elements used to engage M1 differ from those used to engage BMLFl. TCR analyses of
cross-reactive T cell populations revealed that a wide range of Va and Vp families can
mediate interaction with both epitopes. In addition, comparisons of the cross-reactive
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TCR repertoires of several individuals revealed that each repertoire remained unique to
the individual, relying heavily on the clones present in that individual' s private M1- and
BMLF1-specific repertoires. However, TCRs with longer CDR3 regions , often extended
by non-bulky aa residues such as glycine and serine, were more prominent within the
cross-reactive repertoire. These unique features presumably make them more permissible
to interactions with these two dissimilar epitopes. Thus , the cross-reactive repertoire was
more diverse than either non-crossreactive repertoire alone because it included both high
and low frequency clones present in the non-crossreactive M I-specific and non-
crossreactive BMLF1-specific repertoires. If the total number of CDR3 sequences
analyzed within Vp families 14 and 17 are combined, and we compare the total number
of unique Vp-defined clonotypes found in each of the three repertoires of healthy donor
002 , the cross-reactive repertoire (47 unique clonotypes out of 78 total sequences) was
clearly more diverse than that of the M I-specific (41 unique clonotypes out of 146 total
sequences) or BMLF1-specific (13 unique clonotypes out of 115 total sequences)
repertoires. These data suggest that there is great potential for activating M1-specific
memory cells during an acute EBV infection, and the private specificity of each cross-
reactive TCR repertoire provides at least one explanation for the individual variability we
see in the detection of cross-reactive T cell responses with specificity for M1 and
BMLFl.
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CHAPTER 6:
DISCUSSION
Based on work usmg murine models of heterologous viral infection, we
hypothesized that cross-reactive CD8 T cell responses are common components of the
human immune response to viral infection and can influence the outcome of an infection.
Within our model system, we hypothesized that Epstein-Barr virus encodes multiple T
cell epitopes that can activate many cross-reactive T cell responses, especially within
individuals with diverse memory T cell pools due to a long history of previous virus
exposures. We predicted that, collectively, these cross-reactive T cell responses promote
the development of infectious mononucleosis, an immune-mediated pathology associated
with acute EBV infection. This thesis research supports our hypothesis , as we identified
five putative cross-reactive T cell responses that could occur during an acute EBV
infection, including three that would involve the activation of cross-reactive influenza
virus-specific memory T cells. Furthermore, we showed that, at presentation with 1M
patients frequently had an increase in the number of (IV)M1-specific T cells in their
blood, suggesting that a subset of M1-specific memory cells proliferated in response to
this acute EBV infection. We defined at least one cross-reactive T cell response in two
1M patients , with specificity for (IV)M1 and (EBV)BMLFl. Our observation thatthe
M1-specific TCR repertoires of these two patients were highly skewed was an indication
of cross-reactive T cell expansions. This cross-reactive T cell response may have
influenced the severity of 1M, as one of the patients presented as a particularly severe
case, and we have demonstrated that these cross-reactive T cells can produce multiple
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pro-inflammatory cytokines upon stimulation with either epitope. While a direct
correlation between the presence of cross-reactive T cell responses and 1M severity will
require further investigation into the contributions made by cross-reactive responses with
alternative specificites, our data implies that cross-reactive T cells contribute to the
lymphoproliferation charaCteristic of 1M. The data presented here affrmed many of the
observations made on CD8 T cell cross-reactivity and heterologous immunity using a
controlled murine model system and revealed a significant role for cross-reactive T cell
responses on a human disease state.
A; A matrix of cross-reactive T cell specifcities
Upon screening for cross-reactive T cell responses involving EBV-derived HLA-
A2-presented epitopes we detected 5 different cross-reactive specificities and 4 of the 5
specificities involved the EBV -BMLFb80-288 epitope (Chapter III, Figure 29). It is stil
unclear what elements of the BMLF1 epitope structure are used for cross-reactive TCR
interaction, but it is possible that it varies since the majority of the epitopes co-
recognized, derived from EBV and IV, shared little to no sequence homology with
BMLF1. Such a complex matrix of cross-reactive specificity patterns has also been
observed in the murine system, where 5 different cross-reactive specificities involved the
VV-A11RI98 20S epitope (Figure 30) (Cornberg et al. , 2005a). The co-recognized epitopes
were derived from VV, PV and LCMV and the majority of them shared no more than 3
of the 8 aa residues in common with the A11R epitope sequence. Interestingly, the
specific cross-reactive pattern that emerged appeared to depend on the sequence of viral
infections, where A11R-specific T cell lines derived from LCMV-immune mice revealed
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more frequent cross-reactive recognition of LCMV -GP epitopes as opposed to those lines
derived from VV-immune mice that more ftequently demonstrated cross-reactivity with
VV - E7R. Both of these studies , one in mice and one in humans, reveal how prevalent
CD8 T cell cross-reactivity can be and emphasize the fact that having epitope sequence
similarity, referred to as molecular mimicry, is not the only mechanism of T cell cross-
reactivity. A TCR can undergo large conformational changes to accommodate ligands
that one might not predict it could bind (Garcia et al. , 1998). This point has been clearly
demonstrated by Boen and colleagues using a high throughput technology for screening
over 100 000 candidate peptide ligands for a single TCR, where the three stimulatory
peptides identified could not have been predicted based on sequence similarity to the
native ligand (Boen et al. , 2000).
B. The private specifcity of cross-reactive T cell responses
One of the most consistent observations made regarding heterologous immunity
was the variable pattern of T cell cross-reactivity that emerged. For instance, LCMV-
immune mice were protected from VV challenge, and evidence suggested that cross-
reactive memory CD8 T cell responses played a role in this protection (Selin et aI. , 1998).
However, only 50% of LCMV -immune mice challenged with VV mounted a cross-
reactive T cell response specific for the LCMV- 20S 212 epitope, while the other mice
had no evidence of a cross-reactive response or mounted a cross-reactive response with
an alternative specificity (Figure 31) (Kim et al. , 2005). Similar observations were made
in the human system. A cohort of 8 1M patients all had Ml-specific T cells in their
peripheral blood, taken as evidence of exposure to IV prior to EBV infection. However
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only 5 patients had evid nce of M1-specific T cell expansion as a result of EBV infection
and only 2 patients within that group showed evidence of a cross-reactive T cell response
with specificity for M1 and BMLF1 (Chapter IV). These data suggested that not all IV-
immune individuals have cross-reactive M1-specific T cells that co-recognize EBV-
derived antigens and that individuals that do mount a cross-reactive response still differ
by the clonotypic composition of their cross-reactive T cell populations.
The private specificity of a host' s antigen-specific TCR repertoire can influence
the magnitude and specificity of the cross-reactive T cell response. Work from our lab
revealed that the (LCMV)NP-specific T cell response of each mouse was comprised 
unique proportions ofNP-specific Vp families (VP16, 5 and 8.2) and unique clonotypes
within those Vp families, which may explain the observed varability in the specificity of
each cross-reactive response (Kim et al., 2005). Indeed, using adoptive transfer
experiments, we demonstrated that LCMV-immune cells derived from one donor mouse
dictated the cross-reactive response of three recipient mice challenged with VV
justifying the argument that the private epitope-specific repertoire of the immune-host
determined the magnitude and specificity of the cross-reactive response. Although such
controlled experiments are not possible in the human system, we know that the Ml-
specific memory TCR repertoire of each individual is comprised of hundreds of unique
clones (Naumov et al. , 2005; Naumov et al., 2003). In addition, analyses of the cross-
reactive TCR repertoires of 6 different individuals revealed that each included a unique
pattern ofVP usage that was largely influenced by the unique pattern of that individual's
non-crossreactive M1 and BMLF1-specific TCR repertoires (Chapter V). Thus, cross-
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reactive T cell clones are a subset of a clonotypically diverse, private, epitope-specific
TCR repertoire. If the cross-reactive clones of a given specificity represent only a small
proportion of that epitope-specific repertoire, then the cross-reactive response is likely to
be of a lower magnitude than that which occurs when the cross-reactive clones of a given
specificity represent a large proportion of that epitope-specific repertoire.
C. A cross-reactive T cell population is comprised of clones with different
functional avidities and different TCR structures
CD8 T cells can become cytotoxic, secrete cytokines, and proliferate following
their activation. Extensive research on T cell activation using altered peptide ligands has
resulted in the knowledge that T cell effector functions can be segregated and are likely
independently regulated by mechanisms that are stil unclear, but the quantity and quality
of the TCR-mediated signal appear to playa role. Through the study of natural , virus-
induced, cross-reactive CD8 T cell responses, our lab has demonstrated that a cross-
reactive stimulation is more efficient at eliciting cytokine production than proliferation.
For instance, a subset of at least three different LCMV epitope-specific memory T cell
populations produced IFNy 3 days following exposure to VV, suggesting the activation of
a wide range of cross-reactive responses; however, by 12 days after a VV challenge, there
was a significant shift in the typical LCMV epitope-specificity hierarchy, an indication of
the selective proliferation of cross-reactive T cells having only certain epitope-
specificities (Chen et al. , 2001). A similar trend was observed using a second model
system of heterologous immunity, that involving LCMV and PV, whereby a relatively
equal proportion of PV -specific T cells produced IFNy in response to stimulation with
130
either the (PV)NP20s or (LCMV)NP20s peptides (Figure 32) (Cornberg et al. , 2005b).
While this result suggested most (PV)NP-specific cells could function in response to
(LCMV)NP stimulation, longitudinal experiments that followed the initially diverse NP-
specific TCR repertoire of a PV -immune mouse after a challenge with LCMV revealed
that the NP-specific repeitoire narrowed, dominated by T cells expressing only certain
Vp families (Figure 32) (Cornberg et al. , 2005b).
In the human studies presented here, we also saw a hierarchy of functions in
response to a cross-reactive stimulation. We demonstrated that a greater proportion of T
cells responded to cross-reactive stimulation by producing MIP- 1 p than by producing
IFNy, and an even smaller proportion produced TNFa (MIP- 1p::IFNy::TNFa) (Chapter
IV). Although it was not tested directly, we also found that cross-reactive stimulation
was not effcient at inducing T cell proliferation in vitro, as evidenced by the often low
frequencies of cross-reactive cells jn bulk cultures and the lack of long-term cross-
reactive T cell clones.
We observed differences in the functional response to M1 versus BMLF1 peptide
stimulation using two distinct cross-reactive T cell populations (Chapter III). The cross-
reactive population within an M1-specific T cellline produced some IFNy and high levels
of MIP- 1 P to BMLF1 peptide stimulation. In contrast, the cross-reactive population
within a BMLFl-specific T cell line produced only minimal levels of IFNy and no MIP-
1p to M1 peptide stimulation. The functional differences between these two cross-
reactive T cell populations may stem from a difference in the avidity of the interaction
between the TCR and M1 versus the TCR and BMLFl , which can influence the quantity
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and quality of the TCR signal. We did find a difference between these two populations in
the relative avidity for their respective alternative ligand. Based on IFNy production, the
cross-reactive population within the BMLF1-specific line had a higher avidity for its
alternative ligand (M1) than did the cross-reactive population within the M1-specific line
for its alternative ligand (BMLF1) (Chapter III). While these avidity differences may
explain our results, they would go against the paradigm that a higher avidity interaction
results in greater functional capability, unless the M1 peptide is acting as a partial
antagonist in the context of a BMLF1-specific T cell line. Alternatively, the functional
differences between these two cell populations may stem from the qualitative
difference in the TCR signal generated from these two distinct ligands, irrespective of
avidity.
Within a T cell line cultured with M1 and BMLF1 peptides simultaneously, we
were able to compare the functional response of two distinct cross-reactive subsets to the
same peptide ligand (Chapter IV). The T cell subset that co-stained with both M1- and
BMLF1-loaded tetramers produced a hierarchy of cytokines (MIP- IFNy TNFa) in
response to M1 peptide stimulation. In response to this same M1 peptide stimulation, the
T cell subset that only stained with the BMLF1-loaded tetramer produced a lower level of
cytokines overall but exhibited the same profie, in that more MIP- 1 p was produced than
IFNy, and no TNFa production was detected. Based on IFNy production, the relative
avidity for the M1 peptide was higher in the double-tetramer positive subset than in the
single-tetramer subset (Chapter IV). Since, in this case, the stimulating ligand remained
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the same , the differences in the avidity and in the functional response between these two
distinct T cell populations may stem from differences in their TCR repertoires.
Our analyses of cross-reactive TCR repertoires would indeed suggest that
multiple different TCR structures can co-recognize M1 and BMLF1 , as they included a
wide range of Va and Vp. families (Chapter V). Such a diverse array of cross-reactive
TCR structures could indicate that many different structural mechanisms co-exist to
mediate this cross-reactive interaction and that each does so with its own unique avidity.
As mentioned in the introduction to this thesis, there are at least three potential models of
a cross-reactive interaction (Figure 1). The fact that the bulk of our data on cross-reactive
TCR structure was generated using T cell populations, rather than cell clones
precludes us from determining if a cross-reactive T cell expresses two different TCRs and
uses them to interact with both M1 and BMLFl. There is little reason to suspect that
molecular mimicry explains this particular cross-reactive interaction; the two epitopes do
share a valine residue at position 6 of their sequence that appears to be important for
contact with Ml- and BMLFl-specific TCRs (Anels et al. , 2000; Stewart-Jones et al.
2003), but it is unlikely that this shared residue is solely responsible for the specificity of
the interaction. It is more likely that different elements of the cross-reactive TCR are
used to interact with M1 versus BMLF1, a mechanism we refer to as alternative
recognition. Our cross-reactive TCR repertoire analyses support three different models
of alternative recognition (Figure 33). For instance, a cross-reactive TCR may be
comprised of an M1-specific p-chain and a BMLF1-specific a-chain, or vice versa
where it predominantly uses the p-chain to mediate interaction with M1 and the a-chain
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to interact with BMLF 1. This model is plausible knowing that the public specificity of an
M1-specific repertoire includes Vp 17 and that the p-chain mediates much of the contact
with the M1 peptide, whereas the public specificity of a BMLF1-specific repertoire
includes Va15, which is suspected to mediate contact with BMLF1 due to its ability to
pair with multiple Vp families. second model would include cross-reactive cells that
express unique TCRs , not typically detected within M1- or BMLF1-specific populations.
We showed several examples of cross-reactive TCRs that expressed longer CDR3 loops
and that were often comprised of non-bulky aa residues , features which may confer added
flexibility to the TCR and allow it to interact with two structurally dissimilar ligands. We
also detected cross-reactive TCRs that fit a third model of alternative recognition, those
which expressed a CDR3 sequence having features of both Ml- and BMLF1-specific
motifs. In addition to the expression of Vp 17 , the public specificity of an M1-specific
repertoire includes a CDR3p motif of *RS* , the arginine and serine being particularly
important for contact with MI. Interestingly, one of the cross-reactive clones we isolated
expressed a BMLF1-specific V family, Vp2, but the CDR3p sequence was somewhat
atypical in that it included a non-germline encoded serine residue that was positioned
after a conserved arginine residue. Therefore, this cross-reactive TCR CDR3p loop
included an ' RS' sequence that could potentially mediate contact with Ml , while the rest
of the sequence fit the motif of other known BMLFl-specific TCRs. Overall, our data
suggest that multiple different cross-reactive TCR structures exist and support at least 3
different models for the interaction between a cross-reactive TCR and these two
dissimilar ligands, M1 and BMLF1.
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D. The influence of cross-reactive T cell responses on disease pathogenesis and the
memory TCR repertoire
From experiments performed in a murine model system, we know that cross-
reactive LCMV -specific memory T cell responses can alter the disease pathology
associated with acute VV infection. In contrast to the characteristic edema in the lungs of
naIve mice challenged intranasally with VV, the lungs of LCMV-immune mice were
infiltrated with LCMV -specific memory cells and in some cases developed
bronchiolitis obliterans, a pathology where the bronchioles were obstructed with fibrin
and inflammatory cells (Chen et al. , 2001). If delivered intraperitoneally, VV caused
immunopathological lesions in the visceral fat of LCMV -immune mice, which were areas
of necrosis that were also infiltrated with LCMV -specific memory and inflammatory
cells (Selin et al. , 1998; Yang et al. , 1985). It was suspected that the high levels ofIFNy
produced by these immune cells promoted both pathologies and the role ofTNFa is
currently being investigated (Chen et al. , 2001; Selin et al. , 1998).
In this preliminary study of patients with acute EBV infection, we reported one
case where we detected a high level of cross-reactive T cells in the peripheral blood that
co-stained with M1- and BMLF1-loaded tetramers (Chapter IV). This patient presented
with severe clinical signs and symptoms of infectious mononucleosis, which may be
caused by the overall increased level of cytolysis and cytokines at the site of infection
due to the contribution of these and other activated cross-reactive cells. In vitro , we have
demonstrated that cross-reactive cells that co-stain with both M1- and BMLF1-loaded
tetramers can lyse target cells presenting either epitope as well as produce MIP- 1 p, IFNy,
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and TNFa in response to either epitope (Chapter IV). Interestingly, all three cytokine
levels are elevated in the serum and tonsils of 1M patients compared to healthy controls
(Foss et al. , 1994; Iwatsuki et al. , 2004; Nakayama et al. , 2004). MIP- 1 P can be readily
secreted because it is preformed and stored within human CD8 T cells and, therefore
even a low avidity cross-reactive interaction is likely to stimulate its release (Zaitseva et
al. , 2001). MIP-1p acts to broaden the immune response by recruiting other immune
cells to the site of infection, and an increase in the number of activated immune cells will
likely exacerbate the inflammatory response and increase the severity of 1M (De Rosa et
al. , 2004). We showed that fewer cross-reactive T cells secreted high levels of TNFa
which suggested that a higher avidity interaction was required to initiate its release from
the cell. However, an overall increase in the number of responding T cells capable of
secreting TNFa at the site of infection could be harmful to the host and promote the
clinical symptoms of 1M (Vassalli, 1992; Xu et al. , 2004). Although many more patients
wil need to be investigated, these data follow the trend observed in the murine system
which is that cross-reactive T cells have the potential to mediate virus-associated disease
pathology. However, if many cross-reactive T cell responses of different specificities
collectively promote this immune-mediated disease, as we would predict, then a true
correlation may depend on our ability to define and quantify other cross-reactive
specificities in these 1M patients.
The activation of cross-reactive memory cells also has an impact on the memory
TCR repertoire and, consequently, the immune response to subsequent infections. For
instance, a cross-reactive T cell population was previously defined that recognized two
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distinct epitopes derived. from the nucleoproteins of LCMV and PV (Brehm et al. , 2002).
The normally sub-dominant response to PV-NP20S- 2 became dominant upon acute PV
infection of LCMV-immune mice. Following heterologous infection, TCR analyses of
this cross-reactive T cell population revealed the development of a more restricted NP-
specific TCR repertoire compared to that prior to the infection (Cornberg et al. , 2005b).
This cross-reactive repertoire was most often comprised of fewer Vp families and fewer
clonotypes within those Vp families, suggesting that very few cross-reactive clones
proliferated in vivo following heterologous virus infection. While we were unable to
compare the Ml-specific TCR repertoire of the same individual before and during their
acute immune response to EBV infection, we did find that the two 1M patients with
detectable cross-reactive T cells specific for M1 and BMLF1 in their peripheral blood
had M1-specific TCR repertoires that were largely skewed from the conserved clonotypic
pattern typical of an M1-specific TCR repertoire in a resting state (Chapter IV) (Naumov
et aI. , 2005). VP17+ clonotypes using J 3 preferentially expanded in patient Ell01
while those using Jp2.1 preferentially expanded in patient E1l78. While the clonal
difference between these two patients was reflective of the private specificity of their
repertoires , both cases appeared to result in a less diverse M1-specific repertoire than the
typically polyclonal Ml-specific repertoire of healthy IV -immune donors , particularly in
the case of El178 where as few as two unique clonotypes were detected. Based on the
usual dominance of Vp 17 /Jp2. 7 clones, the normally sub-dominant Vp 17 /Jp2.3 and
. Vp17/Jp2. 1 clones may have a relatively lower avidity for the M1 epitope. Thus
skewing of the normal hierarchy of M1-specific clones by cross-reactive clonal T cell
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expansions responding to acute EBV infection may leave these two individuals more
vulnerable to a re-infection with IV and subject to alterations in the disease pathology
associated with re-infection.
E. Cross-reactive T cells commonly contribute to human immune responses
There is likely a role for cross-reactive T cells in the immune response to many
human viral infections. The research presented in this thesis alone demonstrated a cross-
reactive T cell response with specificity for two immunodominant epitopes derived from
two of the most common human viruses among people that share one of the most
common MHC Class I alleles in the U. S.. T cells with this cross-reactive specificity
could be detected in 38% of healthy donors with previous exposure to both viruses
suggesting that these cells can be maintained in memory. In 25% of the patients
investigated, T cells with this particular cross-reactive specificity contributed to the
immune response to acute EBV infection and likely promoted the development of the
immune-mediated infectious mononucleosis syndrome (Chapter IV). Furthermore, T
cells with this cross-reactive specificity can express a variety of TCR structures
including at least 10 different Vp families and at least 9 different Va families (Chapter
V). Thus, the potential is high for activating a cross-reactive T cell clone having this
specificity during infection with either virus.
As is true with EBV, acute HCV infection is often asymptomatic, but when
clinical symptoms manifest, they appear to be immune-mediated. HCV encodes an
epitope, NS31073-IOSl, that can activate influenza A virus NA23-239-specific memory cells
(Wedemeyer et al. , 2001). However, unlike the cross-reactivity between EBV-BMLFI
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and IV- , which are .only 33% similar in sequence, HCV-NS3 and IV-NA are 78%
similar in sequence. The activation of these cross-reactive NA-specific memory cells
enhanced the magnitude, but restricted the specificity, of the CD8 T cell response to HCV
and resulted in severe liver pathology (Urbani et aI. , 2005). Despite their strength in
numbers, these cross-reactive cells were unable to sufficiently clear the virus and the
patients developed persistent HCV infection. Hence , there are now at least two examples
of cross-reactive T cell responses promoting disease pathology associated with two
different viral infections.
Dengue virus infection provides yet another example of a direct correlation
between disease severity and the magnitude of the T cell response (Mongkolsapaya et aI.
2003; Zivna et al. , 2002). Activated T cells are thought to promote the development of
Dengue hemorrhagic fever through the production of harmful inflammatory cytokines
such as TNFa, known to cause plasma leakage (Rothman and Ennis , 1999). This disease
is more commonly associated with secondary Dengue virus infections with a different
serotype to which the individual has no neutralizing antibodies, but does have evidence of
cross-reactive CD8 T cells that can co-recognize epitopes derived from both the primary
and secondary Dengue virus serotype (Mongkolsapaya et aI. , 2003).
Thus , CD8 T cell cross-reactivity may be the rule rather than the exception during
a human immune response. No one is naive, and memory T cells specific to previously
encountered pathogens reside in the body awaiting any opportunity for re-activation to
ensure their long-term survival in a dynamic immune system. The contribution made by
cross-reactive T cells to the immune response can easily go unnoticed
, especially when
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the result is beneficial. As memory cells , they are the first at the site of infection, are at
higher precursor frequencies, and have less requirements for their full activation than do
naIve T cells. If these cross-reactive T cells are efficient at clearing the pathogen, then
often times an infection may be subclinical and wil resolve quickly- It is when these
cross-reactive T cells are inefficient at clearing virus that they cause damage to the host.
They can prolong an infection, perhaps indefinitely in the face of a persistent virus , and
can inhibit an otherwise effcient primary immune response from occurrng. They may
continue to fight a losing battle, secreting multiple cytokines that only exacerbate a
tissue-damaging inflammatory response directly or indirectly through the recruitment of
even more immune cells to the site of infection. In cases such as these, the contribution
of a cross-reactive T cell response may become more obvious, resulting in distinct
disease pathologies.
Due to different histories of infection and the private specificities of T cell
repertoires, establishing a direct cause and effect relationship between a given cross"'
reactive T cell response and disease state may be very diffcult with human studies. That
is why murine models are so important to the research of cross-reactive T cell responses.
Thus far, the concepts leared using these models have translated. into the human system
and have provided keen insight for investigations using human subjects. We must rely on
these models once again for controlled experiments that wil address the mechanism by
which cross-reactive T cells mediate disease pathologies. The knowledge gained by such
research may eventually be used to circumvent, or shift the profie of, a cross-reactive T
cell response before it causes disease or even to specifically target and destroy the
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harmful cross-reactive T cells in the act. As a result, a new trend in medicine may
emerge whereby each case is treated separately. Each individual differs not only by their
genetic make-up but also by their immune system because of the unique number and
sequence of exposures each person has to environmental pathogens.
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